CH1 domain affinity ligands and reagents
By developing affinity ligand based on TPR domain and binding to the CH1 domain of antibody or antibody fragments, the problems of low efficiency and high cost of antibody fragment purification in the prior art are solved, and efficient and stable antibody fragment purification and resin are achieved Reused.
Patent Information
- Application Number
- CN202280092574.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-09-16
- Filing Date
- 2022-12-23
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to effectively purify antibody fragments lacking the IgG large constant region, especially when it is independent of the protein A binding site, resulting in low efficiency and high cost in the purification process.
A TPR domain-based affinity ligand, binding to the CH1 domain of antibody or antibody fragments, was developed for the preparation of affinity reagents and isolation matrix, and efficient purification of antibody fragments is achieved by binding to these ligands.
The efficient purification of antibody fragments and the stability of the reused affinity resin is achieved, reducing purification costs, and maintaining high purity and yield.
Smart Images

Figure BDA0005009952560000361 
Figure BDA0005009952560000371 
Figure BDA0005009952560000381
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This PCT application claims priority to U.S. Provisional Application No. 63 / 293,718 filed on December 24, 2021, U.S. Provisional Application No. 63 / 308,707 filed on February 10, 2022, and U.S. Provisional Application No. 63 / 407,563 filed on September 16, 2022, the entire contents of each of which are incorporated herein by reference. Technical Field
[0003] The present disclosure relates to the field of chromatography, and more specifically, to novel affinity ligands and affinity reagents suitable for separating antibodies and antibody fragments containing the first constant region (CH1) of the heavy chain. The present disclosure includes such affinity ligands, a chromatographic separation matrix (affinity reagent) containing the affinity ligand according to the present disclosure, and a method for separating antibodies, especially IgG and antibody fragments containing CH1 thereof, using the affinity ligand according to the present disclosure. Methods for preparing affinity ligands and separation matrices are also provided. Background Art
[0004] Purity of bioproduced therapeutics is strictly reviewed and regulated by authorities to ensure safety and efficacy. Therefore, there is a need to efficiently purify bioproduced therapeutics to high purity.
[0005] In order to support clinical efforts for therapeutic proteins, compositions and methods for efficient purification of proteins from recombinant sources are needed. Affinity purification is a method for isolating and / or obtaining a protein of desired purity in a few steps or in a single step. However, the development of affinity reagents (e.g., comprising affinity ligands) can be a resource-intensive and time-consuming task, and therefore affinity reagents exist only for very few proteins. In the absence of affinity reagents, purification typically involves inefficient processes, such as multi-column processes.
[0006] Exemplary therapeutic proteins include, but are not limited to, biologically active polypeptides / proteins, fusion proteins, enzymes, hormones, antibodies, and antibody fragments. Certain proteins, such as fusion proteins, present additional challenges to purification due to the homogeneity of the product or the presence of product-related impurities. Some impurities may come from incorrectly assembled fusion proteins and proteolytic cleavage, which may be particularly difficult to remove because they are closely associated with the desired product.
[0007] Affinity reagents that bind proteins and are used for separation and / or affinity purification are described herein.In some embodiments, the affinity reagent comprises a solid support and a ligand.
[0008] Human monoclonal antibody therapeutics are a rapidly growing segment of the biopharmaceutical industry with very promising clinical applications in cancer treatment. Traditional methods for recombinant antibody purification utilize affinity chromatography resins based on the protein A ligand. Protein A-based affinity resins provide an efficient and high-yield method for the purification of monoclonal antibodies, and their use in industrial antibody production processes highlights the need for suitable affinity purification devices.
[0009] The main disadvantage of monoclonal antibody therapy based on immunoglobulin G (IgG) is the poor penetration of very large IgG molecules (about 150 kDa) into tumors. More and more antibody fragments are being studied, which lack the large constant region (Fc region) of IgG. The antibody fragments constructed in this way retain their natural antigen specificity, but lack the ability to bind to Fc receptors. However, such antibody fragments also lack protein A binding sites that can be purified with protein A-based affinity resins, so new methods are needed to purify antibody fragments that cannot bind to protein A resins.
[0010] Exemplary antibody fragment formats currently being studied in clinical trials include, for example, monospecific Fab, monospecific Fab2, bispecific Fab, bispecific Fab2, mono- and bispecific diabodies, triabodies, antibody fragment-drug conjugates, etc. (See Nelson, 2010, mAbs, etc.).
[0011] Many of the above antibody fragments contain a conserved region on the heavy chain, namely the CH1 domain. Affinity agents that bind to the CH1 region of antibodies or antibody fragments will facilitate the separation and / or affinity purification of such fragments. Affinity reagents that bind to antibodies or antibody fragments and are used for separation and / or purification are described herein. In some embodiments, the affinity reagent comprises a solid support and a ligand.
[0012] Tetratricopeptide repeat (TPR) proteins provide a potential scaffold to engineer binding specificity and generate novel binding ligands suitable for such affinity purification. TPRs contain repeating units of a 34 amino acid sequence that adopts a helix-turn-helix structure. Combining three such domains with a seventh helix provides an extended superhelical structure, in which helices 1, 3, 5, and 7 form the inner surface of the superhelix and the binding interface for its target (see Figure 1 ). According to the present disclosure, a series of affinity ligands based on non-naturally occurring TPRs have been developed for binding antibodies or antibody fragments in the CH1 domain. In addition, the resulting TPR domain-based ligands have high stability, including the ability to withstand CIP with NaOH. Overall, these properties make it possible to use affinity ligands that can withstand the harsh conditions of modern bioprocessing. Summary of the invention
[0013] The present disclosure provides affinity ligands that bind antibodies and antibody fragments having or comprising a CH1 domain. Such affinity ligands comprise an amino acid sequence represented by the following formula, from N-terminus to C-terminus,
[0014] [A]-AERWYDLGAAYAARGDX 17a DRAX 21a EX 23a YX 25a RX 27a LEX 30a DPND-
[0015] AWAWWELGX 9b AYAARGDYDRAIEYYQRALELDX 32b NN-
[0016] AVAWARLGIAYAX 13c RGDYDRAIEYYQRALELDPNN-
[0017] EVARX 5d ALEYARRX 13d -[B]
[0018] Where X 17a is F or Y; X 21a is I or T; X 23a is Y or F; X 25a is R or Q; X 27a is T or A; and X 30a is L or H; where X 9b is V or I; and X 32b is L, P or T; where X 13c is T or A; where X 5d is D or G, and X 13d is A or V;
[0019] wherein [A] is present or absent, and when present comprises M, MDE, MGGGGSAAAGDE, MGDE, MGHHHHHHDE, MGLAEAAAREAAARAADE, or MAWAEFRQRLAAIRTRLEALGGSEAELAAFEREIAAFESELQAYAGAGNPEVE ALRREAAAIRDELQAYRHNDE; and wherein [B] is present or absent, and when present comprises cysteine, RRC, RRCHHHHHH, or RRGQAGQGGGSGLNDIFEAQKIEWHECHHHHHH.
[0020] In some embodiments of the affinity ligand, X 17aIt is F;X 21a is I; X 23a It is Y; X 25a Yes R; X 27a It is T; X 30a Yes L; X 9b It is V; X 32b It is P; X 13c It is T; X 5d is D; and X 13d It's V.
[0021] In some embodiments of the affinity ligand, X 17a It is Y; X 21a It is T; X 23a It is F;X 25a It is Q; X 27a It is A; X 30a Yes L; X 9b is I; X 32b It is P; X 13c It is A; X 5d is D; and X 13d It is A.
[0022] In some embodiments of the affinity ligand, X 17a It is Y; X 21a is I; X 23a It is Y; X 25a It is Q; X 27a It is A; X 30a Yes H; X 9b It is V; X 32b It is T; X 13c It is A; X 5d is G; and X 13d It is A.
[0023] In some embodiments of the affinity ligand, X 17a It is Y; X 21a is I; X 23a It is Y; X 25a It is Q; X 27a It is A; X 30a Yes L; X 9b It is V; X 32b Yes L; X 13c It is A; X 5d is D; and X 13d It is A.
[0024] In certain embodiments, [A] is MGHHHHHHDE and [B] is RRC. In certain embodiments, [A] is MGLAEAAAREAAARAADE and [B] is RRCHHHHHH.
[0025] In some embodiments, the affinity ligand comprises any one of Table 9.
[0026] In preferred embodiments, the affinity ligand comprises any one of SEQ ID NO: 89, 128, 129, 130, 131 or 132 ("Ligand 129 Group").
[0027] In preferred embodiments, the affinity ligand comprises any one of SEQ ID NO: 90, 133, 134, 135, 136 or 137 ("ligand 134 group").
[0028] In preferred embodiments, the affinity ligand comprises any one of SEQ ID NO: 139, 140, 141 or 143 ("ligand 141 group").
[0029] In preferred embodiments, the affinity ligand comprises any one of SEQ ID NO: 86, 91, 138, 142, 144, 145, 146, 147 or 148 ("Ligand 144 Group").
[0030] In more preferred embodiments, the affinity ligand comprises any one of SEQ ID NO:129, 134, 141 or 144.
[0031] In some embodiments, affinity ligands of the present disclosure comprise a C-terminal cysteine or lysine.
[0032] Other aspects of the present disclosure relate to multimers comprising a plurality of affinity ligands according to the present disclosure. Such multimers include dimers, trimers, tetramers, pentamers, hexamers, heptamers, octamers and nonamers.
[0033] In other aspects described herein, the affinity ligand or multimer disclosed herein further comprises at least one heterologous agent operably linked to the affinity ligand or multimer to form a conjugate or fusion protein.
[0034] Other aspects of the present disclosure relate to a separation matrix. Such a separation matrix comprises at least one affinity ligand of the present disclosure or at least one multimer of the present disclosure. In an embodiment, the ligand or multimer is coupled to a solid support, optionally via a thiol bond.
[0035] Furthermore, the present disclosure provides a method for isolating an antibody comprising a CH1 domain or a fragment thereof comprising a CH1 domain, the method comprising contacting the antibody or the fragment with the separation matrix of the present disclosure.
[0036] In some embodiments, the method relates to separating or purifying an antibody comprising a CH1 domain or a fragment thereof comprising a CH1 domain, the method comprising (a) contacting a separation matrix of the present disclosure with a composition comprising the antibody or the fragment, (b) washing the separation matrix with a washing buffer, (c) eluting the antibody or the fragment from the separation matrix with an elution buffer, and (d) recovering the antibody or the fragment.
[0037] In some embodiments, the method further comprises (e) treating the separation matrix with an alkaline cleaning solution for a period of time, the time being sufficient to clean the residual material of the matrix and regenerate at least 80% of the antibody- or antibody fragment-binding capacity of the separation matrix. In some embodiments, the alkaline cleaning solution comprises about 0.1M NaOH to about 0.5M NaOH. For example, when steps (a)-(e) are repeated at least 10 times, the separation matrix can retain at least 80% of its antibody or antibody fragment binding capacity. In some embodiments, retain at least 85%, 90% and 95% binding capacity. Similarly, if the binding capacity of the resin is maintained, the same column can be reused for purification, up to at least 10 times or more. This separation matrix is alkali-stable and reduces purification costs.
[0038] Other aspects of the present disclosure relate to nucleic acids or vectors encoding affinity ligands of the present disclosure or multimers of the present disclosure, and expression vectors comprising those nucleic acids or vectors having coding regions of affinity ligands or multimers operably linked to one or more expression control elements. Other embodiments of the present disclosure relate to host cells, particularly Escherichia coli (E. coli) or Pichia pastoris (P. pastoris) for recombinant production of affinity ligands or multimers of the present disclosure.
[0039] In some embodiments, the present disclosure relates to a method of preparing a separation matrix, comprising conjugating a ligand according to the present disclosure or a multimer according to the present disclosure to a solid surface. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 The general ribbon structure of a TPR domain with seven alpha helices, as exemplified by the affinity ligand of the present invention, is shown. Starting from the N-terminus, the seven alpha helices are labeled consecutively, from α1 to α7. The N- and C-termini are also indicated by "N" and "C", respectively.
[0041] Figure 2 Sensorgrams of exemplary affinity reagents are shown. Sensorgrams are biotinylated ligands corresponding to SEQ ID No. 89, SEQ ID No. 90, and SEQ ID No. 92, titrated with indicated concentrations of Herceptin Fab in solution (dark blue, maroon, and light blue lines). The light red line is the best fit curve.
[0042] Figure 3 Sensorgrams of exemplary affinity reagents are shown. The sensorgrams are biotinylated ligands corresponding to SEQ ID No. 89, SEQ ID No. 90, and SEQ ID No. 92, titrated with indicated concentrations of Tremfya Fab in solution (dark blue, maroon, and light blue lines). The light red line is the best fit curve.
[0043] Figure 4 Shown are the adsorption isotherms of the resin prepared from SEQ ID No. 129 before (■) and after (●) incubation in 0.1 M NaOH + 1 M NaCl for 24 hours.
[0044] Figure 5 Shown are the adsorption isotherms of the resin prepared from SEQ ID No. 134 before (■) and after (●) incubation in 0.1 M NaOH + 1 M NaCl for 24 hours.
[0045] Figure 6 Shown are the adsorption isotherms of the resin prepared from SEQ ID No. 144 before (■) and after (●) incubation in 0.1 M NaOH + 1 M NaCl for 24 hours.
[0046] Figure 7 Shown is an SDS-PAGE gel electrophoresis of various fractions obtained from a column purification operation of a monoclonal antibody produced in a CHO cell line under non-reducing conditions using an affinity resin having a ligand of SEQ ID No. 89. The samples in each lane are (1) SeeBlue Plus2 molecular weight marker, (2) crude feed stream (also called CCCF), (3) 10-fold diluted crude feed stream, (4) flow-through fraction, (5) wash fraction, (6) elution fraction (6.4 ug), and (7) wash fraction.
[0047] Figure 8 The residual HCP (upper graph) and residual HCDNA (lower graph) measured after multiple purification cycles of monoclonal antibodies produced in CHO cell lines using affinity resins with ligands of SEQ ID NO. 129 (blue line), 134 (red line) and 144 (yellow line) are shown.
[0048] Fig. 9 The yields measured after multiple cycles of the IgG antibody purification process as described in Example 8 are shown.
[0049] Fig.10Shown is the ForteBio dose response of Trastuzumab and Trastuzufab proteins binding to the biotinylated ligand corresponding to SEQ ID No: 157 immobilized on the sensor.
[0050] Fig.11 The breakthrough curves obtained during the DBC assay of an affinity resin prepared with the ligand corresponding to SEQ ID No: 181 and packed into a 3×50 mm column are shown. and (Bottom) Breakthrough curve obtained using a challenge concentration of 2 g / L at a residence time of 4 minutes.
[0051] Fig.12 The stability of DBC upon exposure to NaOH is shown. Affinity resin prepared with the ligand corresponding to SEQ ID No: 181 was exposed to 1 M NaOH containing 1 M NaCl and DBC was measured at the indicated time points.
[0052] Fig.13 The relative yields obtained for each cycle during the purification of trastuzumab from crude HCCF by repeated cycling of the chromatography column are shown. At the end of each cycle, the column was exposed to 1 M NaOH containing 1 M NaCl for 3.5 hours.
[0053] Fig.14 The residual HCP obtained for each cycle during the purification of trastuzumab from crude HCCF by repeated cycling of the chromatography column is shown. At the end of each cycle, the column was exposed to 1 M NaOH containing 1 M NaCl for 3.5 hours.
[0054] Fig.15 The residual HCP obtained for each cycle during the purification of trastuzumab from crude HCCF by repeated cycling of the chromatography column is shown. At the end of each cycle, the column was exposed to 1 M NaOH containing 1 M NaCl for 3.5 hours. DETAILED DESCRIPTION
[0055] definition
[0056] To make the present disclosure more easily understood, certain terms are defined below. Unless otherwise defined herein, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure relates.
[0057] Units, prefixes and symbols are expressed in a form recognized by the International System of Units (SI). Numerical ranges include numerical values that define the range. Unless otherwise indicated, amino acid sequences are written from left to right in the direction from amino to carboxyl. The titles provided herein are not limitations on the various aspects or embodiments of the present disclosure, which can be obtained by reference to the specification as a whole. Therefore, the terms defined below are more fully defined by reference to the entire content of the specification.
[0058] It should be noted that the term "a" or "an" entity refers to one or more of the entity; for example, "an affinity ligand" is understood to represent one or more affinity ligands. Therefore, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein.
[0059] Approximately or approximately: As used herein, when applied to one or more target values, the term "approximately" or "approximately" refers to a value similar to the reference value. In certain embodiments, the term "approximately" or "approximately" refers to a range of values falling within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction (greater than or less than) of the reference value, unless otherwise stated or apparent from the context (unless the numerical value will exceed 100% of the possible value).
[0060] Bioactive: As used herein, the term "bioactive" refers to the property of any agent that is active in a biological system, particularly in an organism. For example, an agent that has a biological or physiological effect on an organism when administered to the organism is considered bioactive.
[0061] Variants and mutants: The term "variant" is generally defined in the scientific literature and is used herein to refer to an organism that differs genetically in some way from the accepted standard. "Variant" may also be used to describe non-genetic phenotypic differences (King and Stansfield, 2002, Adictionary of genetics, 6th ed., Oxford University Press, New York, NY).
[0062] The term "mutation" is defined in most dictionaries and in this context refers to the process by which a heritable change is introduced into the genetic structure (King & Stansfield, 2002), thereby producing a "mutant". In the scientific and non-scientific literature, the term "variation" is increasingly being used in place of the term "mutation". These terms are used interchangeably in this context.
[0063] Conservative and non-conservative substitutions: A "conservative" amino acid substitution refers to the replacement of one amino acid residue by another amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been defined in the art, including basic side chains (e.g., lysine (K), arginine (R), histidine (H)); acidic side chains (e.g., aspartic acid (D), glutamic acid (E)); uncharged polar side chains (e.g., glycine (G), asparagine (N), glutamine (Q), serine (S), threonine (T), tyrosine (Y), cysteine (C)); non-polar side chains (e.g., alanine (A), valine (V), leucine (L), isoleucine (I), proline (P), phenylalanine (F), methionine (M), tryptophan (W), β-branched side chains (e.g., threonine (T), valine (V), isoleucine (I)); and aromatic side chains (e.g., tyrosine (Y), phenylalanine (P)); Acid (F), tryptophan (W), histidine (H)). For example, replacing tyrosine with phenylalanine is a conservative substitution. In some embodiments, conservative amino acid substitutions in the ligand sequence confer or improve the specific binding of the ligand to the target of interest. In some embodiments, conservative amino acid substitutions in the ligand sequence do not reduce or eliminate the binding of the ligand to the target of interest. In some embodiments, conservative amino acid substitutions do not significantly affect the specific binding of the ligand to the target of interest. Methods for identifying conservative and non-conservative substitutions of nucleotides and amino acids that confer, change or maintain selective binding affinity are known in the art (see, for example, Brummell, Biochem. 32: 1180-1187 (1993); Kobayashi, Protein Eng. 12(10):879-884(1999); and Burks, PNAS 94:412-417(1997)). In some embodiments, non-conservative amino acid substitutions in the ligand sequence confer or improve the specific binding of the ligand to the target of interest. In some embodiments, non-conservative amino acid substitutions in the ligand sequence do not reduce or eliminate the binding of the ligand to the target of interest. In some embodiments, non-conservative amino acid substitutions do not significantly affect the specific binding of the ligand to the target of interest.
[0064] Affinity chromatography: As used herein, the term "affinity chromatography" refers to a specific chromatography mode in which an affinity ligand interacts with a target via bioaffinity in a "lock and key" manner. Examples of useful interactions in affinity chromatography are, for example, enzyme-substrate interactions, biotin-avidin interactions, antibody-antigen interactions, etc.
[0065] Affinity ligand and ligand: The terms "affinity ligand" and "ligand" are used interchangeably herein. These terms are used herein to refer to a molecule that is capable of reversibly binding with high affinity to a moiety (eg, a polypeptide or protein) for which it is specific.
[0066] Protein-based ligand: The term "protein-based ligand" as used herein refers to a ligand comprising a peptide or protein or a portion of a peptide or protein that reversibly binds to a target polypeptide or protein. It should be understood that a "ligand" of the present disclosure is a protein-based ligand.
[0067] Affinity reagent: As used herein, the term "affinity reagent" refers to a solid support or matrix to which a biospecific affinity ligand is covalently attached. Typically, the solid support or matrix is insoluble in the system for purifying the target molecule. The terms "affinity reagent" and "affinity separation matrix (CES)" and "separation matrix (CES)" are used interchangeably herein.
[0068] Linker: As used herein, "linker" refers to a peptide or other chemical bond whose function is to connect independent functional domains. In some embodiments, the linker is located between a ligand and another polypeptide component containing an independent function or domain. In some embodiments, the linker is a peptide or other chemical bond located between a ligand and a surface.
[0069] Naturally occurring: When used with biological materials such as nucleic acid molecules, polypeptides, and host cells, the term "naturally occurring" refers to those materials found in nature and have not been modified by humans. In contrast, "non-natural" or "synthetic" when used with biological materials refers to those materials that are not found in nature and / or have not been modified by humans.
[0070] "Non-natural amino acids," "amino acid analogs," and "non-standard amino acid residues" are used interchangeably herein. Non-natural amino acids that can be substituted in the ligands provided herein are known in the art. In some embodiments, the non-natural amino acid is 4-hydroxyproline, which can be substituted for proline; 5-hydroxylysine, which can be substituted for lysine; 3-methylhistidine, which can be substituted for histidine; homoserine, which can be substituted for serine; and ornithine, which can be substituted for lysine. Other examples of non-natural amino acids that can be substituted in the polypeptide ligand include, but are not limited to, molecules such as: D isomers of common amino acids, 2,4-diaminobutyric acid, α-aminoisobutyric acid, A-aminobutyric acid, Abu, 2-aminobutyric acid, γ-Abu, ε-Ahx, 6-aminohexanoic acid, Aib, 2-aminoisobutyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteine, tert-butylglycine, tert-butylalanine, phenylglycine, cyclohexylalanine, β-alanine, lanthionine, dehydroalanine, γ-aminobutyric acid, selenocysteine and pyrrolysine, fluoroamino acids, designer amino acids such as β-methyl amino acids, Cα-methyl amino acids and Nα-methyl amino acids.
[0071] "Polynucleotide" and "nucleic acid molecule": As used interchangeably herein, polynucleotide and nucleic acid molecule refer to a polymeric form of nucleotides (ribonucleotides or deoxyribonucleotides) of any length. These terms include, but are not limited to, DNA, RNA, cDNA (complementary DNA), mRNA (messenger RNA), rRNA (ribosomal RNA), shRNA (small hairpin RNA), snRNA (small nuclear RNA), snoRNA (small nucleolar RNA), miRNA (micro RNA), genomic DNA, synthetic DNA, synthetic RNA, and / or tRNA (transfer RNA).
[0072] Operably linked: As used herein, the term "operably linked" means that two or more components are arranged so that these components function normally and allow the possibility that at least one component can mediate the function exerted on at least one other component. Whether two molecules are directly linked or indirectly linked, they are "operably linked".
[0073] Peptide tag: The term "peptide tag" as used herein refers to a peptide sequence that is part of another protein or is connected (e.g., by genetic engineering) to another protein, thereby providing a function for the resulting fusion. These functions include, but are not limited to, changing the solubility of the protein, regulating the expression of the protein, and promoting the connection or interaction of the protein with another entity. Peptide tags are usually, but not always, relatively short compared to the proteins to which they are fused. In some embodiments, the length of the peptide tag is four or more amino acids, such as 5, 6, 7, 8, 9, 10, 15, 20 or 25 or more amino acids. In some embodiments, the peptide tag used herein includes a second protein that can act as a "tag" (e.g., GFP) or promoter of a specific property. In some embodiments, the ligand is a protein comprising a peptide tag. Many peptide tags with uses provided herein are known in the art. Examples of peptide tags that can be used as components of ligand fusion proteins or as targets bound by ligands (e.g., ligand fusion proteins) include, but are not limited to, HA (hemagglutinin), c-myc, herpes simplex virus glycoprotein D (gD), T7, GST, GFP, MBP, streptococcal tags, His tags, Myc tags, TAP tags, and FLAG tags (Eastman Kodak, Rochester, New York). Likewise, antibodies to tag epitopes allow for detection and localization of fusion proteins in, for example, affinity purification, Western blotting, ELISA assays, and cell immunostaining.
[0074] Polypeptide: As used herein, the term "polypeptide" refers to a chain of amino acid sequences linked together by peptide bonds. The term is used to refer to a chain of amino acids of any length, but one of ordinary skill in the art will understand that the term is not limited to long chains, and can refer to a minimal chain comprising two amino acids linked together by a peptide bond. As known to those skilled in the art, polypeptides can be processed and / or modified.
[0075] Protein: As used herein, the term "protein" refers to one or more polypeptides that function as discrete units. If a single polypeptide is a discrete functional unit and does not require permanent or temporary physical association with other polypeptides to form a discrete functional unit, then the terms "polypeptide" and "protein" are used interchangeably. If the discrete functional unit is composed of more than one polypeptide physically associated with each other, then the term "protein" refers to multiple polypeptides that are physically associated and function together as a discrete unit.
[0076] Specific binding: As used herein, with respect to a ligand, the term "specific binding" or "having a selective affinity for it" refers to a ligand that reacts or binds more frequently, more rapidly, longer, with higher affinity, or a combination of the above to a specific epitope, protein, or target molecule rather than to other substances, including unrelated proteins. Due to sequence identity between homologous proteins in different species, specific binding can include binding agents that recognize proteins or targets in more than one species, for example, being bispecific or trispecific. Similarly, due to homology within certain regions of the polypeptide sequences of different proteins, specific binding can include binding agents that recognize more than one protein or target. It should be understood that in certain embodiments, a binding agent that specifically binds to a first target may or may not specifically bind to a second target. Similarly, "specific binding" does not necessarily require (although it can include) exclusive binding, i.e., binding to a single target. Therefore, in certain embodiments, a ligand or affinity agent can specifically bind to more than one target. In certain embodiments, multiple targets can be bound by the same binding site on an affinity agent.
[0077] Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting a characteristic or property of interest in full or nearly full extent or degree. One of ordinary skill in the biological arts will appreciate that biological and chemical phenomena are rarely, if ever, completed and / or performed to perfection or to achieve or avoid an absolute result. Therefore, the term "substantially" is used herein to represent the potential imperfections inherent in many biological and chemical phenomena.
[0078] CH1 domain affinity ligand
[0079] The affinity ligands of various aspects and embodiments of the present disclosure are high affinity protein ligands that reversibly bind to antibodies and antibody fragments that contain the first constant region (CH1) of the heavy chain (referred to herein as "CH1 domain"). This binding allows these protein ligands to be particularly useful for separating and / or purifying antibodies and any antibody fragments that lack an Fc domain but retain a heavy chain CH1 region.
[0080] The affinity ligand of the present disclosure comprises an amino acid sequence represented by the following formula, from N-terminus to C-terminus,
[0081] [A]-AERWYDLGAAYAARGDX 17a DRAX 21a EX 23a YX 25a RX 27a LEX 30a DPND-AWAWWELGX 9b AYAARGDYDRAIEYYQRALELDX 32b NN-AVAWARLGIAYAX 13c RGDYDRAIEYYQRALELDPNN-EVARX 5d ALEYARRV-[B]
[0082] Where X 17a is F or Y; X 21a is I or T; X 23a is Y or F; X 25a is R or Q; X 27a is T or A; X 30a is L or H;
[0083] Where X 9b is V or I; and X 32b is L, P or T;
[0084] Where X 13c is T or A;
[0085] Where X 5d is D or G, and X 13d is A or V; and
[0086] wherein [A] is present or absent, and when present comprises M, MDE, MGGGGSAAAGDE, MGDE, MGHHHHHHDE, MGLEAEAAREAAARAADE, or MAWAEFRQRLAAIRTRLEALGGSEAELAAFEREIAAFESELQAYAGAGNPEVEALRREAAAIRDELQAYRHNDE; and [B] is present or absent, and when present comprises cysteine, RRC, RRCHHHHHH, or RRGQAGQGGGSGLNDIFEAQKIEWHECHHHHHH. These affinity ligands bind antibodies and antibody fragments comprising a CH1 domain.
[0087] The affinity ligands of the present invention are derived from a protein containing a TPR domain having three repeats of a 34 amino acid TPR domain followed by a seventh helix. Each repeat encodes a helix-turn-helix motif, which is a typical motif in proteins containing TPR domains. For clarity, the three 34 amino acid domains are colinear in the ligand, but appear on a line so that the first amino acid on the line is amino acid 1 of the 34 amino acid domain. Thus, the first TPR domain (as shown above) comprises helix 1 and helix 2, the second TPR domain comprises helix 3 and helix 4, and the third TPR domain comprises helix 5 and helix 6. In the present disclosure, "a", "b" and "c" are also used to represent the three TPR domains in these affinity ligands.
[0088] In some embodiments, the affinity ligands disclosed herein have the above general formula, wherein X 17a It is F;X 21a is I; X 23a It is Y; X 25a Yes R; X 27a It is T; X 30a Yes L; X 9b It is V; X 32b It is P; X 13c It is T; X 5d is D; and X 13d is V. In some embodiments, the affinity ligands include, but are not limited to, those comprising SEQ ID NO. 89, 128, 129, 130, 131, or 132. Such embodiments are also referred to as the ligand 129 group.
[0089] In some embodiments, the affinity ligands disclosed herein have the above general formula, wherein X 17a It is Y; X 21a It is T; X 23a It is F;X 25a It is Q; X 27a It is A; X30a Yes L; X 9b is I; X 32b It is P; X 13c Yes A; X 5d is D; and X 13d is A. In some embodiments, the affinity ligands include, but are not limited to, those comprising SEQ ID NO. 90, 133, 134, 135, 136, or 137. Such embodiments are also referred to as the ligand 134 group.
[0090] In some embodiments, the affinity ligands disclosed herein have the above general formula, wherein X 17a It is Y; X 21a is I; X 23a It is Y; X 25a It is Q; X 27a Yes A; X 30a Yes H; X 9b It is V; X 32b It is T; X 13c Yes A; X 5d is G; and X 13d is A. In some embodiments, the affinity ligands include, but are not limited to, those comprising SEQ ID NO. 139, 140, 141, or 143. Such embodiments are also referred to as the ligand 141 group.
[0091] In some embodiments, the affinity ligands disclosed herein have the above general formula, wherein X 17a It is Y; X 21a is I; X 23a It is Y; X 25a It is Q; X 27a Yes A; X 30a Yes L; X 9b It is V; X 32b Yes L; X 13c Yes A; X 5d is D; and X 13d A. In some embodiments, the affinity ligands include, but are not limited to, those comprising SEQ ID NO. 86, 91, 138, 142, or 144-148. Such embodiments are also referred to as ligand 144 group.
[0092] In some embodiments of the affinity ligand, [A] is MGHHHHHHDE and [B] is RRC. In some embodiments of the affinity ligand, [A] is MGLAEAAAREAAARAADE and [B] is RRCHHHHHH.
[0093] In some embodiments, provided herein is an affinity reagent comprising a TPR ligand, wherein the TPR ligand comprises seven helices, wherein the first helix comprises the sequence SEQ ID NO: IX 1 RxF 2 X 3 , where X 1 is A, D, E, G, N, Q, S, or V; X 2 is A, E, W or Y; X 3 is D, G, I, N, T, V, W or Y;
[0094] The third helix comprises the sequence SEQ ID NO:2
[0095] X 4 AWX 5 X 6 LGX 7 , where X 4 It is W; X 5 is E or W; X 6 is D, E or H; X 7 It is T, V, W;
[0096] The fifth helix comprises the sequence SEQ ID NO:3
[0097] X 8 AWX 9 X 10 LGX 11 , where X 8 is A, H, I, T or V; X 9 is A, F, N, S or R; X 10 Yes R; X 11 is F, I, H or W; and
[0098] The seventh helix comprises the sequence SEQ ID NO:4
[0099] X 12 ARX 13 X 14 LEX 15 , where X 12 is A, L, T or V; X 13 is A, D, E, H, Q, R, S, or Y; X 14 is A, E, I, L, N or Q; X 15 is A, D, E, H, N, R, S, V or Y. In some embodiments, provided herein is an affinity reagent comprising a TPR ligand comprising seven helices, wherein the first helix comprises the sequence SEQ ID NO: 1
[0100] X 1 RxF 2X 3 , where X 1 is D or E, Q or V; X 2 is E or Y; X 3 is D, I or N;
[0101] The third helix comprises the sequence SEQ ID NO:2
[0102] X 4 AWX 5 X 6 LGX 7 , where X 4 It is W; X 5 It is W; X 6 Yes E; X 7 is I or V;
[0103] The fifth helix comprises the sequence SEQ ID NO:3
[0104] X 8 AWX 9 X 10 LGX 11 , where X 8 is H, T or V; X 9 A, F or S; X 10 Yes R; X 11 is H, I or W; and
[0105] The seventh helix comprises the sequence SEQ ID NO:4
[0106] X 12 ARX 13 X 14 LEX 15 , where X 12 is A, L, T or V; X 13 is D, H, R or Y; X 14 is A, I, V or L; X 15 It is D, H, V or Y.
[0107] In some embodiments, provided herein is an affinity reagent comprising a TPR ligand, wherein the TPR ligand comprises seven helices, wherein the first helix comprises the sequence SEQ ID NO: 1
[0108] X 1 RxF 2 X 3 , where X 1 Yes N; X 2 It is Y; X 3 is V or Y;
[0109] The third helix comprises the sequence SEQ ID NO:2
[0110] X 4 AWX 5 X 6 LGX 7 , where X 4 is F or Y; X 5 Yes D; X 6 Yes E; X 7 is N or S;
[0111] The fifth helix comprises the sequence SEQ ID NO:3
[0112] X 8 AWX 9 X 10 LGX 11 , where X 8 It is V; X 9 is N or S; X 10 Yes R; X 11 is H or Q; and the seventh helix comprises the sequence SEQ ID NO:4
[0113] X 12 ARX 13 X 14 LEX 15 , where X 12 is T or V; X 13 is H or T; X 14 Yes L; X 15 is Q or W. In some embodiments, provided herein is an affinity reagent comprising a TPR ligand, wherein the TPR ligand comprises 7 helices, wherein the first helix comprises the sequence SEQ ID NO: 1
[0114] X 1 RxF 2 X 3 , where X 1 It is A; X 2 Yes E; X 3 is F or V;
[0115] The third helix comprises the sequence SEQ ID NO:2
[0116] X 4 AWX 5 X 6 LGX 7 , where X 4 It is W; X 5 Yes E; X 6 Yes H; X 7 It is W;
[0117] The fifth helix comprises the sequence SEQ ID NO:3
[0118] X 8 AWX 9 X 10 LGX 11 , where X 8 Yes H; X 9 It is F;X 10 Yes R; X 11 is F; and
[0119] The seventh helix comprises the sequence SEQ ID NO:4
[0120] X 12 ARX 13 X 14 LEX 15 , where X 12 L or Q; X 13 A or E; X 14 is E or Q; X 15 It is S or H.
[0121] In some embodiments, provided herein is an affinity reagent comprising a TPR ligand, wherein the TPR ligand comprises seven helices, wherein the first helix comprises the sequence SEQ ID NO: 1
[0122] X 1 RxF 2 X 3 , where X 1 is A, D, E, L, Q or V; X 2 is A, D, E or W; X 3 is A, D, F, I, N, V, W or Y;
[0123] The third helix comprises the sequence SEQ ID NO:2
[0124] X 4 AWX 5 X 6 LGX 7 , where X 4 It is W; X 5 is E or W; X 6 is D, E or H; X 7 is L, V or W;
[0125] The fifth helix comprises the sequence SEQ ID NO:3
[0126] X 8 AWX 9 X 10 LGX 11 , where X 8 is H, R or V; X 9 It is F;X 10Yes R; X 11 is F or W; and
[0127] The seventh helix comprises the sequence SEQ ID NO:4
[0128] X 12 ARX 13 X 14 LEX 15 , where X 12 Is L or T; X 13 is A, D, E or R; X 14 is E, I, Q or V; X 15 It is D, E, G, H, S or N.
[0129] In some embodiments, provided herein is an affinity reagent comprising a TPR ligand, wherein the TPR ligand comprises seven helices, wherein the first helix comprises the sequence SEQ ID NO: IX 1 RxF 2 X 3 , where X 1 is D, E or S; X 2 It is Y; X 3 is D, Y or H;
[0130] The third helix comprises the sequence SEQ ID NO:2
[0131] X 4 AWX 5 X 6 LGX 7 , where X 4 It is W; X 5 It is W; X 6 Yes E; X 7 is V, T or A;
[0132] The fifth helix comprises the sequence SEQ ID NO:3
[0133] X 8 AWX 9 X 10 LGX 11 , where X 8 is V or I; X 9 is A, F or S; X 10 Yes R; X 11 is H or W;
[0134] The seventh helix comprises the sequence SEQ ID NO:4
[0135] X 12 ARX 13 X 14 LEX 15 , where X12 A, L or V; X 13 A, H or S; X 14 is A, E, L or N; X 15 It is A, N, V or Y.
[0136] In some embodiments, affinity agents bind to the CH1 domain of monoclonal antibody molecules and fragments.
[0137] In some embodiments, provided herein is an affinity reagent comprising a ligand that binds to an antibody or antibody fragment comprising the sequence, SEQ ID No: 153
[0138] &&&&&&&&X 1 RxF 2 X 3 &&&&&&&&&&&&&&&&&&&&&&&&&&&&&X 4 AWX 5 X 6 LGX 7 &&&&&&&&&&&&&&&&&&&&&&&&&&&&&X 8 AWX 9 X 10 LGX 11 &&&&&&&&&&&&&&&&&&&&&&&&&&&&&X 12 ARX 13 X 14 LEX 15 , wherein & represents any amino acid; X 1 is A, D, E, G, N, Q, S, or V; X 2 is A, E, W or Y; X 3 is D, G, H, I, N, T, V, W, or Y; X 4 It is W; X 5 is E or W; X 6 is D, E or H; X 7 It is T, V, W; X 8 AWX 9 X 10 LGX 11 , where X 8 is A, H, I, T or V; X 9 is A, F, N, S or R; X 10 Yes R; X 11 is F, I, H or W; X 12 ARX 13 X 14 LEX 15 , where X 12 is A, L, T or V; X 13is A, D, E, H, Q, R, S, or Y; X 14 is A, E, I, L, N or Q; X 15 Is A, D, E, H, N, R, S, V, or Y.
[0139] In some embodiments, provided herein is an affinity reagent comprising a ligand that binds to an antibody or antibody fragment comprising the sequence, SEQ ID No: 5
[0140] X 1 RxF 2 X 3 LGAAYAARGDYDRAIEYYQRALELDPNNAX 4 AWX 5 X 6 LGX 7 AYAARGDYDRAIEYYQRALELDPNNAX 8 AWX 9 X 10 LGX 11 AYAARGDYDRAIEYYQRALELDPNNEX 12 ARX 13 X 14 LEX 15 , where X 1 It is Q, D, A, G, E, V, N; X 2 It is E, A, Y, Q; X 3 Is D, N, G, V, I, T, W, Y; X 4 It is W; X 5 It is W, E; X 6 It is E, D, H; X 7 It is V, W, T; X 8 It is V, H, T, A, I; X 9 It is F, R, S, A, N; X 10 Yes R; X 11 It is H, W, F, I; X 12 It is L, T, V; X 13 It is E, Y, R, A, D, S, Q; X 14 It is Q, L, E, I, A; X 15 It is H, D, Y, S, E or R.
[0141] In some embodiments, the affinity reagent comprises a ligand comprising any one of the amino acid sequences shown in Table 1, such as any one of SEQ ID NOs: 6-152.
[0142] In some embodiments, provided herein are affinity reagents comprising a ligand comprising SEQ ID NO: 6-152, or an amino acid sequence that differs by no more than 3, no more than 2, or no more than 1 substitution, addition, or deletion.
[0143] In some embodiments, the affinity ligands of the present disclosure comprise a C-terminal cysteine or lysine, preferably cysteine.
[0144] Another aspect of the present disclosure provides a multimer comprising at least two subunits (e.g., at least two affinity ligands of the present disclosure). Such a plurality can be homogeneous (i.e., a single ligand of the present invention) or heterogeneous (i.e., comprising two or more different ligands of the present invention). In other words, in some embodiments, an affinity reagent comprising a multimeric polypeptide is provided herein, wherein the subunits are not identical. In embodiments, the multimer can be a dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, or nonamer.
[0145] In a further aspect of the present disclosure, the affinity ligand or its polymer further comprises at least one heterologous agent operably linked to the affinity ligand, thereby forming a conjugate or fusion protein. Examples of heterologous agents include, but are not limited to, one or more small molecule diagnostic or therapeutic agents; peptide tags (as defined herein), DNA, RNA or hybrid DNA-RNA molecules; traceable markers; radioactive materials; antibodies; single-chain variable domains; or immunoglobulin fragments. Such conjugates and fusion proteins can be prepared by methods known in the art.
[0146] Ligands that bind to antibodies or antibody fragments having a CH1 domain
[0147] The characteristics of a ligand or multimer that binds to a target (eg, an antibody or fragment thereof having a CH1 domain) can be determined using known or modified assays, bioassays, and / or animal models known in the art for assessing such activity.
[0148] As used herein, terms such as "binding affinity for a target," "binding to a target," "binding to an antibody or fragment thereof having a CH1 domain," and the like refer to properties of the ligands of the present disclosure that can be measured directly, for example, by determining an affinity constant (e.g., the amount of ligand bound and dissociated at a given antigen concentration). A variety of methods can be used to characterize such molecular interactions, for example, competition assays, equilibrium assays, and microcalorimetry, as well as real-time interaction assays based on surface plasmon resonance interactions (e.g., using a BIACORE instrument). These methods are well known to those skilled in the art and are discussed in publications such as Neri D et al. (1996) Tibtech 14:465-470 and Jansson M et al. (1997) J Biol Chem 272:8189-8197.
[0149] The affinity requirement for a given ligand binding event depends on a variety of factors, including but not limited to the composition and complexity of the binding matrix, the valency and density of the ligand and target molecule, and the functional application of the ligand. In some embodiments, the ligands of the invention are bound at a density of less than or equal to 5×10 -3 M, 10 -3 M, 5×10 -4 M, 10 -4 M, 5×10 -5 M or 10 -5 The dissociation constant (KD) of M binds to an antibody or fragment thereof having a CH1 domain. In some embodiments, the ligand binds to an antibody or fragment thereof with a dissociation constant (KD) of less than or equal to 5×10 -6 M, 10 -6 M, 5×10 -7 M, 10 -7 M, 5×10 -8 M or 10 -8 In some embodiments, the ligand binds to the target of interest with a KD of less than or equal to 5×10 -9 M, 10 -9 M, 5×10 -10 M, 10 -10 M, 5×10 -11 M, 10 -11 M, 5×10 -12 M, 10 -12 M, 5×10 -13 M, 10 -13 M, 5×10 -14 M, 10 -14 M, 5×10 -15 M or 10 -15 In some embodiments, the ligands produced by the methods disclosed herein have a KD of about 10 -4 M to about 10-5 M, about 10 -5 M to about 10 -6 M, about 10 -6 M to about 10 -7 M, about 10 -7 M to about 10 - 8 M, about 10 -8 M to about 10 -9 M, about 10 -9 M to about 10 -10 M, about 10 -10 M to about 10 -11 M or about 10 -11 M to about 10 -12 dissociation constant of M.
[0150] Determine K D The binding experiments to determine K and the dissociation rate can be carried out under various conditions. Those skilled in the art can easily determine the buffer for preparing these solutions, which largely depends on the desired pH value of the final solution. For example, low pH solutions (<pH 5.5) can be prepared in citrate buffer, glycine-HCl buffer or succinate buffer. For example, high pH solutions can be prepared in Tris-HCl, phosphate buffer or sodium bicarbonate buffer. For the purpose of determining, for example, the optimal pH and / or salt concentration, many conditions can be used to determine K D and the dissociation rate.
[0151] In some embodiments, the ligand or multimer of the present invention has a k within the range of 0.1 to 10 -7 sec -1 、10 -2 to 10 -7 sec -1 or 0.5x10 -2 to 10 -7 sec -1 and specifically binds to an antibody having a CH1 domain or a fragment thereof. In some embodiments, the ligand has a dissociation rate (k 解离 ) of less than 5x10 -2 sec -1 、10 -2 sec -1 、5x10 -3 sec -1 or 10 -3 sec -1 when binding to the target of interest. In some embodiments, the ligand has a dissociation rate of less than 5x10 解离 ) of less than 5x10 -4 sec -1 、10 -4 sec-1 , 5x10 -5 sec -1 or 10 - 5 sec -1 , 5x10 -6 sec -1 , 10 -6 sec -1 , 5x10 -7 sec -1 or 10 -7 sec -1 The dissociation rate (k 解离 ) binds to the target of interest.
[0152] In some embodiments, the ligand or polymer is present in an amount of about 10 3 Up to 10 7 M -1 sec -1 , 10 3 Up to 10 6 M -1 sec -1 or 10 3 Up to 10 5 M -1 sec -1 k in the range 结合 Specifically binds to an antibody or fragment thereof having a CH1 domain. In some embodiments, the ligand (e.g., ligand fusion protein) is present at a concentration of greater than 10 3 M -1 sec -1 , 5x10 3 M -1 sec -1 , 10 4 M -1 sec -1 or 5x10 4 M -1 sec -1 The binding rate (k 结合 ) binds to the target of interest. In another embodiment, the ligand is present in an amount greater than 10 5 M -1 sec -1 , 5x10 5 M -1 sec -1 , 10 6 M -1 sec -1 , 5x10 6 M -1 sec -1 or 10 7 M -1 sec-1 K 结合 Bind to target of interest.
[0153] Connectors
[0154] The terms "linker" and "spacer" are used interchangeably herein and refer to peptides or other chemical connections whose function is to connect independent functional domains. In some embodiments, the linker is located between a ligand and another polypeptide component containing an independent functional domain. Suitable linkers for coupling two or more connected ligands can generally be any linker used in the art for connecting peptides, proteins or other organic molecules. In some embodiments, such linkers are suitable for constructing proteins or polypeptides intended for pharmaceutical use.
[0155] Suitable linkers for operably linking the ligand and additional components of the ligand fusion protein in the single-chain amino acid sequence include, but are not limited to, polypeptide linkers, such as glycine linkers, serine linkers, mixed glycine / serine linkers, glycine- and serine-rich linkers, or linkers consisting primarily of polar polypeptide fragments.
[0156] In some embodiments, the joint comprises a majority of amino acids selected from glycine, alanine, proline, asparagine, glutamine and lysine. In some embodiments, the joint comprises a majority of amino acids selected from glycine, alanine, proline, asparagine, aspartic acid, threonine, glutamine and lysine. In some embodiments, the ligand joint is composed of a majority of amino acids with less steric hindrance. In some embodiments, the joint comprises a majority of amino acids selected from glycine, serine and / or alanine. In some embodiments, the joint is selected from polyglycine (e.g., (Gly) 5 and (Gly) 8, poly (Gly-Ala)) and polyalanine.
[0157] The joint can be any size or composition, as long as they can be operably connected to the ligand in a manner that allows the ligand to bind the target of interest. In some embodiments, the joint is about 1 to 50 amino acids, about 1 to 20 amino acids, about 1 to 15 amino acids, about 1 to 10 amino acids, about 1 to 5 amino acids, about 2 to 20 amino acids, about 2 to 15 amino acids, about 2 to 10 amino acids or about 2 to 5 amino acids. It should be clear that the length of the joint, the degree of flexibility and / or other properties may affect some properties of the part used for affinity reagents, such as to the target of interest, or to one or more other target proteins of interest, or to the affinity, specificity or avidity (avidity) of non-target proteins (i.e., non-target proteins). In some embodiments, two or more joints are used. In some embodiments, two or more joints are identical. In some embodiments, two or more joints are different.
[0158] In some embodiments, the linker is a non-peptide linker, such as an alkyl linker or a PEG linker. For example, an alkyl linker such as -NH-(CH2) can be used. s -C(0)-, wherein s=2-20. These alkyl linkers can be further substituted with any less hindered group, such as lower alkyl (e.g., C1-C6), lower acyl, halogen (e.g., Cl, I, Br, F), CN, NH2, phenyl, etc. An exemplary non-peptide linker is a PEG linker. In some embodiments, the molecular weight of the PEG linker is about 100 to 5000 kDa, or about 100 to 500 kDa.
[0159] Linkers can be evaluated using techniques described herein and / or known in the art.In some embodiments, the linker does not alter (eg, does not destroy) the ability of the ligand to bind to the target molecule.
[0160] Affinity reagents comprising conjugated ligands: affinity separation matrices
[0161] Ligands or polymers that promote specific binding to the target of interest can be chemically conjugated to various surfaces used in chromatography, such as beads, resins, gels, membranes, monoliths, etc. to prepare affinity reagents. The affinity reagents disclosed herein are particularly useful for purification and production applications of antibodies or fragments thereof having a CH1 domain.
[0162] In some embodiments, the ligand of the present disclosure (e.g., ligand fusion protein) comprises at least one reactive residue. Reactive residues are useful, for example, as sites for connecting conjugates such as chemotherapeutic drugs or diagnostic agents. Exemplary reactive amino acid residues include, for example, lysine or cysteine. Reactive residues can be added to either end of the ligand, or within the ligand sequence, and / or can replace another amino acid within the ligand sequence. Suitable reactive residues (e.g., lysine, cysteine, etc.) can also be located in the sequence of the identified ligand without addition or replacement.
[0163] Attaches to solid surfaces
[0164] "Solid surface," "support," or "matrix" are used interchangeably herein and refer, without limitation, to any column (or column material), bead, test tube, microtiter plate, solid particle (e.g., agarose or gel), microchip (e.g., silica gel, silica glass, or gold chip), or membrane (synthetic (e.g., filter) or biological (e.g., liposome or vesicle)) to which a ligand or multimer of the invention may be attached (i.e., coupled, linked, or adhered) directly or indirectly (e.g., through other binding partner intermediates such as linkers) or in which a ligand or multimer may be embedded (e.g., through receptors or channels). Reagents and techniques for attaching polypeptides to solid supports are well known in the art, such as carbamate coupling. Suitable solid supports include, but are not limited to, chromatographic resins or matrices (e.g., SEPHAROSE-4FF agarose beads), the walls or bottoms of wells in plastic microtiter dishes, silicon-based biochips, polyacrylamide, agarose, silica, nitrocellulose, paper, plastic, nylon, metal, and combinations thereof. Ligands and other compositions can be attached to support materials by non-covalent binding or covalent bonding using reagents and techniques known in the art. In some embodiments, a linker is used to couple the ligand to the chromatography material.
[0165] In one aspect, the present disclosure provides an affinity reagent (affinity separation matrix) consisting of a ligand or polymer as described above coupled to an insoluble support. This support can be one or more particles, such as beads; membranes; filters; capillaries; monoliths; and any other form commonly used in chromatography. In a favorable embodiment of the affinity separation matrix, the support is composed of substantially spherical particles, also referred to as beads. Suitable particle sizes can be in the range of 5-500 μm in diameter, such as 10-100 μm, such as 20-80 μm. In an alternative embodiment, the support is a membrane. In order to obtain a high adsorption capacity, the support is preferably porous, and the ligand can be coupled to the outer surface as well as the pore surface. In a favorable embodiment of this aspect, the support is porous.
[0166] In another aspect, the present disclosure relates to a method for preparing a chromatographic affinity reagent, the method comprising providing a ligand as described above, and coupling the ligand to a support. For example, coupling can be performed through a nitrogen or sulfur atom of the ligand. The ligand can be coupled to the support directly or indirectly through a spacer element to provide an appropriate distance between the support surface and the ligand. Methods for immobilizing protein ligands to porous or non-porous surfaces are well known in the art.
[0167] Ligand generation
[0168] The production of ligands and polymers that can be used to implement multiple embodiments of the present disclosure can be carried out using various standard techniques of chemical synthesis, semi-synthetic methods and recombinant DNA methodology known in the art. A method for producing a ligand or polymer is also provided, either alone or as part of a multi-domain fusion protein, as a soluble reagent and a cell-associated protein. In some embodiments, the overall production scheme of a ligand or polymer includes obtaining a reference protein scaffold and determining multiple residues within the scaffold for modification. Depending on the embodiment, the reference scaffold may include a protein structure having one or more α-helical regions, or other tertiary structures. Once determined, any one of the multiple residues can be modified, for example, by substitution of one or more amino acids. In some embodiments, one or more conservative substitutions are made. In some embodiments, one or more non-conservative substitutions are made. In some embodiments, a natural amino acid (e.g., one of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine) is substituted into the reference scaffold at the target position for modification. In some embodiments, the modification does not include substitution of cysteine or proline. In specific embodiments, after modification at the desired identification position, the resulting modified polypeptide (e.g., candidate ligand) can be recombinantly expressed in, for example, a plasmid, bacteria, phage, or other vector (e.g., to increase the number of each modified polypeptide). The modified polypeptides can then be purified and screened to identify those modified polypeptides that have specific binding to a specific target of interest (e.g., an antibody or fragment thereof having a CH1 domain). Compared to the benchmark scaffold, the modified polypeptide may exhibit enhanced binding specificity to an antibody or fragment thereof having a CH1 domain, or may exhibit little or no binding to a given target of interest (or non-target protein). In some embodiments, depending on the target of interest, the benchmark scaffold may show some interactions (e.g., nonspecific interactions) with the target of interest, while certain modified polypeptides will show an increase in binding specificity to the target of interest by at least about 2 times, at least about 5 times, at least about 10 times, at least about 20 times, at least about 50 times, or at least about 100 times (or more). Additional details on the production, selection, and separation of ligands are provided in more detail below.
[0169] Recombinant expression of ligands
[0170] In some embodiments, the ligand, such as a ligand fusion protein, is "recombinantly produced" (i.e., produced using recombinant DNA technology). Exemplary recombinant methods that can be used to synthesize ligand fusion proteins include, but are not limited to, polymerase chain reaction (PCR)-based synthesis, concatenation, seamless cloning, and recursive directional ligation (RDL) (see, e.g., Meyer et al., Biomacromolecules 3:357-367 (2002), Kurihara et al., Biotechnol. Lett. 27:665-670 (2005), Haider et al., Mol. Pharm. 2:139-150 (2005); and McMillan et al., Macromolecules 32 (11):3643-3646 (1999)).
[0171] On the other hand, nucleic acids comprising polynucleotide sequences encoding ligands or polymers according to the above disclosed embodiments are also provided. Therefore, the present disclosure includes all forms of nucleic acid sequences of the present invention, such as RNA and DNA encoding polypeptides (ligands) or polymers. The present invention provides vectors, such as plasmids, which, in addition to coding sequences, also comprise signal sequences required for expressing polypeptides or polymers according to the present disclosure. Such polynucleotides optionally also comprise one or more expression control elements. For example, the polynucleotides may comprise one or more promoters or transcription enhancers, ribosome binding sites, transcription termination signals, and polyadenylation signals as expression control elements. The polynucleotides may be inserted into any suitable vector, which may be included in any suitable host cell for expression. In one embodiment, the vector comprises nucleic acids encoding polymers according to the present disclosure, wherein the independent nucleic acids encoding each unit may have homologous or heterologous DNA sequences.
[0172] The expression of nucleic acids encoding ligands and polymers is usually achieved by operably linking the nucleic acids encoding the ligands to a promoter in an expression vector. Typical expression vectors include transcription and translation terminators, initiation sequences, and promoters for regulating the expression of the desired nucleic acid sequence. Exemplary promoters for expression in Escherichia coli include, for example, the T7 promoter.
[0173] Methods known in the art can be used to construct expression vectors containing nucleic acid sequences encoding ligands and suitable transcription / translation control signals. These methods include, but are not limited to, in vitro recombinant DNA techniques, synthetic techniques, and in vivo recombination / genetic recombination. The expression of polynucleotides can be carried out in any suitable expression host known in the art, including but not limited to bacterial cells, yeast cells, insect cells, plant cells, or mammalian cells. In some embodiments, the nucleic acid sequence encoding the ligand is operably linked to a suitable promoter sequence so that the nucleic acid sequence is transcribed and / or translated into the ligand in the host.
[0174] A variety of host expression vector systems can be used to express nucleic acids encoding ligands. Carriers containing nucleic acids encoding ligands (e.g., single ligand subunits or ligand fusions) or parts or fragments thereof include plasmid vectors, single-stranded and double-stranded phage vectors, and single-stranded and double-stranded RNA or DNA viral vectors. Phage and viral vectors can also be introduced into host cells in the form of packaged or encapsulated viruses using known infection and transduction techniques. In addition, viral vectors can be normal to replicate, or replication-defective. Alternatively, cell-free translation systems can also be used to produce proteins using RNA from DNA expression constructs (see, e.g., WO86 / 05807 and WO89 / 01036; and U.S. Patent No. 5,122,464).
[0175] Generally, any type of cell or cultured cell line can be used to express the ligand or polymer provided herein. In some embodiments, the background cell line for producing engineered host cells is a phage, a bacterial cell, a yeast cell or a mammalian cell. A variety of host expression vector systems can be used to express the coding sequence of the ligand fusion protein. Mammalian cells can be used as host cell systems, which are transfected with recombinant plasmid DNA or cosmid DNA expression vectors, and the expression vector contains the coding sequence of the target of interest and the coding sequence of the fusion polypeptide. The cell can be a primary isolate from an organism, a culture or a transformed or transgenic cell line.
[0176] Suitable host cells include, but are not limited to, microorganisms, such as bacteria (e.g., Escherichia coli, Bacillus subtilis) transformed with a recombinant phage DNA, plasmid DNA or cosmid DNA expression vector containing a ligand encoding sequence; yeast (e.g., Saccharomyces, Pichia) transformed with a recombinant yeast expression vector containing a ligand encoding sequence; insect cell systems infected with a recombinant virus expression vector (e.g., baculovirus) containing a ligand encoding sequence; plant cell systems infected with a recombinant virus expression vector (e.g., cauliflower mosaic virus (CaMV); tobacco mosaic virus (TMV)) or transformed with a recombinant plasmid expression vector (e.g., Ti plasmid) containing a ligand encoding sequence.
[0177] Prokaryotes that can be used as host cells to produce ligands include gram-negative or gram-positive organisms, such as Escherichia coli and Bacillus subtilis. Expression vectors for prokaryotic host cells generally contain one or more phenotypic selection marker genes (e.g., genes encoding proteins that confer antibiotic resistance or provide autotrophic requirements). Examples of useful prokaryotic host expression vectors include pKK223-3 (Pharmacia, Uppsala, Sweden), pGEM1 (Promega, Wis., the U.S.), pET (Novagen, Wis., the U.S.) and pRSET (Invitrogen, Calif., the U.S.) series vectors (see, e.g., Studier, J. Mol. Biol. 219: 37 (1991) and Schoepfer, Gene 124: 83 (1993)). Exemplary promoter sequences commonly used in prokaryotic host cell expression vectors include T7 (Rosenberg et al., Gene 56:125-135 (1987)), β-lactamase (penicillinase), lactose promoter system (Chang et al., Nature 275:615 (1978)); and Goeddel et al., Nature 281:544 (1979)), tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res. 8:4057, (1980)), and tac promoter (Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).
[0178] In some embodiments, a eukaryotic host cell system is used, including yeast cells transformed with a recombinant yeast expression vector containing a ligand coding sequence. Exemplary yeasts that can be used to produce the disclosed compositions include yeasts from the genus Saccharomyces, the genus Pichia, the genus Actinomycetes, and the genus Kluyveromyces. Yeast vectors typically include a replication origin sequence, an autonomous replication sequence (ARS), a promoter region, a polyadenylation sequence, a transcription termination sequence, and a selective marker gene from a 2mu yeast plasmid. Examples of promoter sequences in yeast expression constructs include promoters from metallothionein, 3-phosphoglycerate kinase (Hitzeman, J. Biol. Chem. 255: 2073 (1980)) and other glycolytic enzymes, such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other suitable vectors and promoters for yeast expression and yeast transformation protocols are known in the art. See, for example, Fleer, Gene 107:285-195 (1991) and Hinnen, PNAS 75:1929 (1978).
[0179] Insect and plant host cell culture systems can also be used to produce the compositions of the present invention. Such host cell systems include, for example, insect cell systems infected with recombinant viral expression vectors (e.g., baculovirus) containing ligand coding sequences; plant cell systems infected with recombinant viral expression vectors (e.g., cauliflower mosaic virus (CaMV); tobacco mosaic virus (TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing ligand coding sequences, including but not limited to U.S. Patent No. 6,815,184, U.S. Patent Publication Nos. 60 / 365,769 and 60 / 368,047, and WO2004 / 057002, WO2004 / 024927, and WO2003 / 078614.
[0180] In some embodiments, host cell systems can be used, including animal cell systems infected with recombinant viral expression vectors (e.g., adenovirus, retrovirus, adeno-associated virus, herpes virus, lentivirus), including cell lines engineered to contain multiple copies of DNA encoding a ligand that is stably amplified (CHO / dhfr) or unstably amplified in a double minute chromosome (e.g., a mouse cell line). In some embodiments, the vector comprising a polynucleotide encoding a ligand is a polycistronic. Exemplary mammalian cells for producing these compositions include 293 cells (e.g., 293T and 293F), CHO cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 (Crucell, Netherlands) cells VERY, Hela cells, COS cells, MDCK cells, 3T3 cells, W138 cells, BT483 cells, Hs578T cells, HTB2 cells, BT20 cells, T47D cells, CRL7O30 cells, HsS78Bst cells, hybridoma cells and other mammalian cells. Other exemplary mammalian host cells that can be used to implement the disclosed embodiments include, but are not limited to, T cells. Exemplary expression systems and selection methods are known in the art and include those described in the following references and references cited therein: Borth et al., Biotechnol. Bioen. 71(4):266-73 (2000), in Werner et al., Arzneimittelforschung / Drug Res. 48(8):870-80 (1998), Andersen et al., Curr. Op. Biotechnol. 13:117-123 (2002), Chadd et al., Curr. Op, Biotechnol. 12:188-194 (2001), and Giddings, Curr. Op. Biotechnol. 12:450-454 (2001). Other examples of expression systems and selection methods are described in Logan et al., PNAS 81:355-359 (1984), Birtner et al. Methods Enzymol. 153:51-544 (1987). Transcriptional and translational control sequences for mammalian host cell expression vectors are often derived from viral genomes. Commonly used promoter sequences and enhancer sequences in mammalian expression vectors include sequences from polyoma virus, adenovirus 2, simian virus 40 (SV40), and human cytomegalovirus (CMV). Exemplary commercially available expression vectors for mammalian host cells include pCEP4 (Invitrogen) and pcDNA3 (Invitrogen).
[0181] Physical methods for introducing nucleic acids into host cells (e.g., mammalian host cells) include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, etc. Methods for generating cells containing vectors and / or exogenous nucleic acids are well known in the art. See, e.g., Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York).
[0182] Biological methods for introducing target polynucleotides into host cells include the use of DNA and RNA vectors. Viral vectors, especially retroviral vectors, have become the most widely used methods for inserting genes into mammalian (e.g., human) cells. Other viral vectors can be derived from lentiviruses, poxviruses, herpes simplex virus I, adenoviruses, and adeno-associated viruses, etc. See, for example, U.S. Patent Nos. 5,350,674 and 5,585,362.
[0183] Methods for introducing target DNA and RNA polynucleotides into host cells include electroporation of cells, in which an electric field is applied to the cells to increase the permeability of the cell membrane, thereby allowing chemicals, drugs or polynucleotides to be introduced into the cells. Electroporation can be used to introduce DNA or RNA constructs containing ligands into mammalian or prokaryotic cells.
[0184] In some embodiments, electroporation of cells results in expression of the ligand CAR on the surface of T cells, NK cells, or NKT cells. This expression may be transient or stable throughout the life cycle of the cell. Electroporation can be accomplished using methods known in the art, including MaxCyte and Transfection system (MaxCyte, Gaithersburg, MD, USA).
[0185] Chemical methods for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle). In the case of using a non-viral delivery system, an exemplary delivery vehicle is a liposome. It is contemplated that a lipid formulation is used to introduce nucleic acid into a host cell (in vitro, in vitro, or in vivo). In some embodiments, nucleic acid is associated with lipids. Nucleic acids bound to lipids can be encapsulated in the aqueous interior of liposomes, dispersed in the lipid bilayer of liposomes, connected to liposomes by connecting molecules bound to liposomes and oligonucleotides, embedded in liposomes, compounded with liposomes, dispersed in a solution containing lipids, mixed with lipids, combined with lipids, contained in lipids as a suspension, contained in micelles or compounded with micelles, or otherwise combined with lipids. Lipids, lipid / DNA, or lipid / expression vector-related compositions are not limited to any specific structure in solution. For example, they can exist in a double-layer structure, micelles, or "folded" structures. They may also simply be dispersed in solution, possibly forming aggregates of inconsistent size or shape. Lipids are fatty substances that can be naturally occurring or synthetic. For example, lipids include naturally occurring fat droplets in the cytoplasm, as well as a class of compounds containing long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.
[0186] Suitable lipids can be obtained from commercial sources. For example, dimyristoylphosphatidylcholine ("DMPC") can be obtained from Sigma, St. Louis, MO; dihexadecyl phosphate ("DCP") can be obtained from K&K Laboratories (Plainview, New York); cholesterol ("Choi") can be obtained from Calbiochem-Behring; dimyristoylphosphatidylglycerol ("DMPG") and other lipids can be obtained from Avanti Polar Lipids, Inc. (Birmingham, AL). Stock solutions of lipids in chloroform or chloroform / methanol can be stored at about -20°C. Chloroform can be used as the only solvent because it evaporates more easily than methanol. "Liposome" is a general term that includes various monolayer and multilayer lipid carriers formed by creating closed lipid bilayers or aggregates. Liposomes are characterized by having a vesicular structure with a phospholipid bilayer membrane and an internal aqueous medium. Multilayer liposomes have multiple lipid layers separated by an aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before forming a closed structure and trap water and dissolved solutes between the lipid bilayers (Ghosh et al., Glycobiology 5:505-510 (1991)). However, compositions having structures that differ from normal vesicle structures in solution are also included. For example, the lipids may assume a micellar structure or exist simply as heterogeneous aggregates of lipid molecules. Liposome-nucleic acid complexes are also contemplated.
[0187] Regardless of the method used to introduce exogenous nucleic acid into the host cell, the presence of the recombinant nucleic acid sequence in the host cell can generally be confirmed by various assays known in the art. These assays include, for example, "molecular biology" assays, such as Southern and Northern blots, RT-PCR and PCR; "biochemical" assays, such as detecting the presence or absence of specific peptides, such as by immunological methods (ELISA and Western blots) or by assays described herein to identify agents within the scope of the present invention.
[0188] Reporter genes are used to identify possible transfected cells and to assess the function of regulatory sequences. Generally speaking, reporter genes are genes that are not present in or expressed by recipient organisms, tissues or cells, and the expression of the polypeptides encoded by them is demonstrated by some easily detectable characteristics, such as enzyme activity. After DNA is introduced into recipient cells, the expression of reporter genes is measured at the appropriate time. Suitable reporter genes include, but are not limited to, genes encoding luciferase, beta-galactosidase, chloramphenicol acetyltransferase, secretory alkaline phosphatase, or green fluorescent protein genes (e.g., Ui-Tei et al., FEBS Lett.479:79-82 (2000)). Suitable expression systems are known in the art and can be prepared or obtained from the market using known techniques. Typically, constructs with the minimum 5' flanking region showing the highest expression level of reporter genes are identified as promoters. This promoter region can be routinely connected to a reporter gene and used to assess the ability of the reagent for regulating promoter-driven transcription.
[0189] Many selection systems are available for mammalian host-vector expression systems, including but not limited to the herpes simplex virus thymidine kinase, hypoxanthine-guanine phosphoribosyltransferase, and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes. In addition, antimetabolite resistance can be used as the basis for selection, for example, dhfr, gpt, neo, hygro, trpB, hisD, ODC (ornithine decarboxylase), and glutamine synthase systems.
[0190] In some embodiments, the starting material N-terminal methionine is contained at the NH-terminus of the ligand. In many cases, the ligand is isolated without an N-terminal methionine residue, presumably cleaved during expression. In many cases, only a portion of the purified ligand in the resulting mixture contains an N-terminal methionine. It will be apparent to one skilled in the art that the presence or absence of the N-terminal methionine does not affect the function of the ligands and affinity reagents described herein.
[0191] Ligand purification
[0192] Once a ligand or ligand fusion protein or polymer is produced by recombinant expression, it can be purified by methods known in the art for purifying recombinant proteins, for example, by chromatography (e.g., ion exchange, affinity and size column chromatography), centrifugation, differential solubility, or by any other standard technique for protein purification. In some embodiments, the ligand is optionally fused to a heterologous polypeptide sequence specifically disclosed herein or known in the art to facilitate purification. In some embodiments, the ligands (e.g., antibodies and other affinity matrices) of the ligand affinity column used for affinity purification and, optionally, other components of the ligand or ligand fusion composition to which these ligands bind are removed from the composition prior to the final preparation of the ligand using techniques known in the art.
[0193] Chemical synthesis of ligands
[0194] In addition to recombinant methods, the production of ligands can also be carried out using organic chemical synthesis of the desired polypeptide using various liquid and solid phase chemical methods known in the art. Various automatic synthesizers are commercially available and can be used according to known protocols. See, e.g., Tam et al., J. Am. Chem. Soc., 105:6442 (1983); Merrifield, Science, 232:341-347 (1986); Barany and Merrifield, The Peptides, Gross and Meienhofer, eds., Academic Press, New York, 1-284; Barany et al., Int. J. Pep. Protein Res., 30:705-739 (1987); Kelley et al. in Genetic Engineering Principles and Methods, Setlow, JK, ed., Plenum Press, New York 1990, Vol. 12, pp. 1-19; Stewart et al., Solid-Phase Peptide Synthesis, WH Freeman Co., San Francisco, 1989. One advantage of these methods is that they allow the incorporation of non-natural amino acid residues into the ligand sequence.
[0195] The ligands and multimers used in the disclosed methods can be modified during or after synthesis or translation, for example, by glycosylation, acetylation, benzylation, phosphorylation, amidation, pegylation, formylation, derivatization by known protecting / blocking groups, proteolytic cleavage, attachment to antibody molecules, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, ubiquitination, and the like. (See, e.g., Creighton, Proteins: Structures and Molecular Properties, 2nd ed., (WH Freeman and Co., New York, 1992); Postranslational Covalent Modification of Proteins, Johnson, ed., (Academic Press, New York, 1983), pp. 1-12; Seifter, Meth. Enzymol., 182: 626-646 (1990); Rattan, Ann. NY Acad. Sci., 663: 48-62 (1992)). In some embodiments, the peptide is acetylated at the N-terminus and / or amidated at the C-terminus.
[0196] Any of a number of chemical modifications may be performed by known techniques, including but not limited to acetylation, formylation, etc. Additionally, the derivatives may comprise one or more non-classical amino acids.
[0197] In some embodiments, cyclization or macrocyclization of the peptide backbone is achieved by side chain to side chain ligation. Methods for achieving this are well known in the art and may include natural and non-natural amino acids. Methods include disulfide formation, lanthionine formation or thiol alkylation (e.g., Michael addition), amidation between amino and carboxylate side chains, click chemistry (e.g., azide-alkyne condensation), peptide stapling, ring-closing translocation, and the use of enzymes.
[0198] Purification of affinity reagents
[0199] In affinity chromatography-based purification, the target of interest (e.g., protein or molecule) is selectively isolated based on its ability to specifically and reversibly bind to a ligand, which is typically covalently coupled to a chromatographic matrix. The affinity ligands disclosed herein can be used as reagents for affinity purification of antibodies or fragments thereof having a CH1 domain from clarified cell culture fluid (CCCF) or natural sources such as biological samples (e.g., serum), for example, from synthetic or recombinant production of these antibody fragments, or from classical enzymatic digestion of whole antibodies.
[0200] In some embodiments, a ligand or multimer that specifically binds to an antibody or fragment thereof having a CH1 domain is immobilized on beads, such as agarose beads, to form an affinity separation matrix, which is then used to affinity purify the target.
[0201] The method of covalently coupling protein to surface is known to those skilled in the art, and the peptide tag that can be used to connect the ligand to the solid surface is known to those skilled in the art. In addition, the ligand can be connected (that is, coupled, connected or adhered) to the solid surface using any reagent or technology known in the art. In some embodiments, the solid support includes beads, glass, slides, chips and / or gelatin. Therefore, using technology known in the art, a series of ligands can be used to form arrays on solid surfaces. U.S. Patent Publication No. 2004 / 0009530 discloses a method for preparing an array, and the patent is incorporated herein by reference.
[0202] In some embodiments, the ligand or polymer is used to separate antibodies or fragments thereof having a CH1 domain by affinity chromatography. In some embodiments, the ligand or polymer is fixed on a solid support. The ligand or polymer can be fixed on a solid support using techniques and reagents described herein or known in the art. Suitable solid supports are described herein or known in the art, and are suitable for filling chromatography columns in specific embodiments. Affinity reagents can be filled in columns of various sizes and operated at various linear speeds, or fixed affinity ligands can be contacted with a solution under conditions that are conducive to forming a complex between the ligand and the antibody or fragment thereof having a CH1 domain. Non-binding materials can be washed away. Suitable washing conditions can be easily determined by those skilled in the art. Examples of suitable washing conditions are described in Shukla and Hinckley, Biotechnol Prog. 2008 Sep-Oct; 24 (5): 1115-21. doi: 10.1002 / btpr.50.
[0203] In some embodiments, chromatography is performed by mixing a solution containing a target of interest and a ligand, and then separating a complex of the target of interest and the ligand (e.g., an antibody or fragment thereof having a CH1 domain and a ligand). For example, the ligand or multimer is immobilized on a solid support such as a bead, and then separated from the solution together with the antibody or fragment thereof having a CH1 domain by filtration. In some embodiments, the ligand or multimer is a fusion protein containing a peptide tag, such as a polyhistidine tail or a streptavidin protein binding region, which can be used to separate the ligand or multimer after forming a complex using an immobilized metal affinity chromatography resin or a streptavidin protein coated substrate. Once separated, the antibody or fragment thereof having a CH1 domain can be released from the ligand or multimer under elution conditions and recovered in a purified form.
[0204] In some embodiments, the ligand or polymer of the present invention is coupled to a highly cross-linked agarose base matrix, which can be used for bioprocess applications. The connection of the ligand or polymer to the base matrix can be through a flexible spacer, which ensures the accessibility of the ligand and subsequently leads to high binding capacity. The affinity of the ligand and polymer of the present invention ensures highly specific binding of antibodies or fragments thereof with CH1 domains at a near-neutral pH (pH 6-9), while being able to be eluted at a pH of up to 4.5. In addition, the ligand of the present invention is designed for enhanced alkaline stability, enabling the repeated use of 0.1M to 0.5M NaOH in cleaning-in-place (CIP) and sanitary treatment applications.
[0205] On the other hand, the present disclosure provides a method for separating an antibody or a fragment thereof having a CH1 domain, wherein the separation matrix disclosed above is used. In certain embodiments, the method comprises the following steps: (a) contacting a liquid sample containing an antibody or a fragment thereof having a CH1 domain with a separation matrix as described above, (b) washing the separation matrix with a washing solution, (c) eluting the antibody or a fragment thereof having a CH1 domain from the separation matrix with an elution solution, and (d) cleaning the separation matrix with a cleaning solution, which may alternatively be referred to as a cleaning in situ (CIP) solution, for example, a contact (incubation) time of at least one minute, for example, one to four minutes or more.
[0206] Suitable compositions of liquid samples, washing solutions and eluents and general conditions for separation are well known in the field of affinity chromatography. The liquid sample comprising an antibody or fragment thereof having a CH1 domain may contain host cell proteins (HCP), such as HEK293T cells. The host cell proteins may be desorbed in step (b).
[0207] Binding to antibodies or fragments thereof having a CH1 domain has been demonstrated using buffers at near neutral pH (6-9) over a wide range of ionic strengths (e.g., 100-400 mM NaCl). Conventional buffers, such as phosphate, citrate, acetate, Tris, can be used for equilibration and loading.
[0208] In some embodiments, before the solution is contacted with the separation matrix, the solution or sample containing the antibody or its fragment having the CH1 domain is concentrated, for example, by ultrafiltration. For example, a solution containing the antibody or antibody fragment, such as a clarified cell culture feed, can be concentrated up to 20 times. The concentration of the antibody or antibody fragment reduces the loading time of the affinity chromatography. Due to the thermodynamic equilibrium effect, the increase in concentration may also have a positive effect on the binding capacity, which may result in a lower volume of the separation matrix required for purification. The feed of the concentrated antibody or antibody fragment solution can also significantly speed up the processing time.
[0209] Alternatively, the solution or sample containing the antibody or fragment thereof having a CH1 domain is a non-concentrated or diluted solution, such as clarified cell culture feed (CCCF). Figure 4 As shown, the affinity separation matrix of the present disclosure is characterized by the ability to process CCCF at high volumetric flow rates, enabling capture from dilute CCCF feed streams.
[0210] Elution of the antibody or fragment thereof is typically achieved by lowering the pH, for example to 2.0-3.0, although higher pH may be used. The optimal conditions for elution of the antibody or fragment thereof having a CH1 domain can be readily determined by one skilled in the art.
[0211] The affinity reagents of the present disclosure are alkali resistant, enabling cleaning with NaOH concentrations up to 0.5 M. In certain embodiments, for example, a CIP protocol with exposure to 0.5 M NaOH for up to 30 to 60 minutes per cycle ensures consistent chromatographic performance over several cycles (e.g., 15-30 cycles), including up to 70%-90% of the initial binding capacity and low residual DNA and HCP levels, and essentially no flow variation.
[0212] Although some embodiments of the present invention have been described by way of example, it is obvious that the present invention may be implemented through numerous modifications, variations and adaptations, and by using numerous equivalents or alternative solutions within the purview of those skilled in the art, without departing from the essence of the invention or exceeding the scope of the claims.
[0213] All publications, patents, and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
[0214] Exemplary embodiments
[0215] 1. An affinity reagent, comprising a ligand, wherein the ligand comprises a TPR ligand comprising 7 helices, wherein the first helix comprises the sequence SEQ ID NO: 1
[0216] X 1 RxF 2 X 3 , where X 1 is A, D, E, G, N, Q, or V; X 2 is A, E, W or Y; X 3 is D, G, H, I, N, T, V, W or Y;
[0217] The third helix comprises the sequence SEQ ID NO:2
[0218] X 4 AWX 5 X 6 LGX 7 , where X 4 It is W; X 5 is E or W; X 6 is D, E or H;
[0219] X 7 It is T, V, W;
[0220] The fifth helix comprises the sequence SEQ ID NO:3
[0221] X 8 AWX 9 X 10 LGX 11 , where X 8 is A, H, I, T or V; X 9 is A, F, N, S or R; X 10 Yes R; X 11 is F, I, H or W; and
[0222] The seventh helix comprises the sequence SEQ ID NO:4
[0223] X 12 ARX 13 X 14 LEX 15 , where X 12 is A, L, T or V; X 13 is A, D, E, H, Q, R, S, or Y; X 14 is A, E, I, L, N or Q; X 15 Is A, D, E, H, N, R, S, V, or Y.
[0224] 2. Affinity reagent, comprising a TPR ligand, wherein the TPR ligand comprises 7 helices, wherein the first helix comprises the sequence SEQ ID NO: 1
[0225] X 1 RxF 2 X 3 , where X 1 is E, Q or V; X 2 is E or Y; X 3 is D, I or N;
[0226] The third helix comprises the sequence SEQ ID NO:2
[0227] X 4 AWX 5 X 6 LGX 7, where X 4 It is W; X 5 It is W; X 6 Yes E; X 7 is I or V;
[0228] The fifth helix comprises the sequence SEQ ID NO:3
[0229] X 8 AWX 9 X 10 LGX 11 , where X 8 is H, T or V; X 9 is A, F or S; X 10 It is R;
[0230] X 11 is H, I or W; and
[0231] The seventh helix comprises the sequence SEQ ID NO:4
[0232] X 12 ARX 13 X 14 LEX 15 , where X 12 is L, T or V; X 13 is D, R or Y; X 14 is A, I or L; X 15 It is D, H or Y.
[0233] 3. Affinity reagent, comprising a TPR ligand, wherein the TPR ligand comprises 7 helices, wherein the first helix comprises the sequence SEQ ID NO: 1
[0234] X 1 RxF 2 X 3 , where X 1 Yes N; X 2 It is Y; X 3 is V or Y;
[0235] The third helix comprises the sequence SEQ ID NO:2
[0236] X 4 AWX 5 X 6 LGX 7 , where X 4 is F or Y; X 5 Yes D; X 6 Yes E; X 7 is N or S;
[0237] The fifth helix comprises the sequence SEQ ID NO:3
[0238] X 8 AWX 9 X 10 LGX 11 , where X 8 It is V; X 9 is N or S; X 10 Yes R; X 11 is H or Q; and
[0239] The seventh helix comprises the sequence SEQ ID NO:4
[0240] X 12 ARX 13 X 14 LEX 15 , where X 12 is T or V; X 13 is H or T; X 14 Yes L; X 15 It is Q or W.
[0241] 4. Affinity reagent, comprising a TPR ligand, wherein the TPR ligand comprises 7 helices, wherein the first helix comprises the sequence SEQ ID NO: 1
[0242] X 1 RxF 2 X 3 , where X 1 Yes A; X 2 Yes E; X 3 is F or V;
[0243] The third helix comprises the sequence SEQ ID NO:2
[0244] X 4 AWX 5 X 6 LGX 7 , where X 4 It is W; X 5 Yes E; X 6 Yes H; X 7 It is W;
[0245] The fifth helix comprises the sequence SEQ ID NO:3
[0246] X 8 AWX 9 X 10 LGX 11 , where X 8 Yes H; X 9 It is F;X 10 Yes R; X 11 is F; and
[0247] The seventh helix comprises the sequence SEQ ID NO: 4X 12 ARX 13 X 14 LEX 15 , where X 12 L or Q; X 13 A or E; X 14 is E or Q; X 15 It is S or H.
[0248] 5. An affinity reagent, comprising a TPR ligand, wherein the TPR ligand comprises 7 helices, wherein the first helix comprises the sequence SEQ ID NO: 1
[0249] X 1 RxF 2 X 3 , where X 1 is A, D, E, L, Q or V; X 2 is A, D, E or W;
[0250] X 3 is A, D, F, I, N, V, W or Y;
[0251] The third helix comprises the sequence SEQ ID NO:2
[0252] X 4 AWX 5 X 6 LGX 7 , where X 4 It is W; X 5 is E or W; X 6 is D, E or H;
[0253] X 7 is L, V or W;
[0254] The fifth helix comprises the sequence SEQ ID NO:3
[0255] X 8 AWX 9 X 10 LGX 11 , where X 8 is H, R or V; X 9 It is F;X 10 Yes R; X 11 is F or W; and
[0256] The seventh helix comprises the sequence SEQ ID NO:4
[0257] X 12 ARX 13 X 14LEX 15 , where X 12 Is L or T; X 13 is A, D, E or R; X 14 is E, I, Q or V; X 15 It is D, E, G, H, S or N.
[0258] 6. The affinity reagent of embodiment 1, which binds to a monoclonal antibody, an antibody fragment, and an antibody conjugate containing a CH1 domain.
[0259] 7. Affinity reagent, the affinity reagent comprising a ligand, the ligand comprising the sequence SEQ ID NO: 5
[0260] X 1 RxF 2 X 3 LGAAYAARGDYDRAIEYYQRALELDPNNAX 4 AWX 5 X 6 LGX 7 AYAARGDYDRAIEYYQRALELDPNNAX 8 AWX 9 X 10 LGX 11 AYAARGDYDRAIEYYQRALELDPNNEX 12 ARX 13 X 14 LEX 15 ,
[0261] Where X 1 is A, D, E, G, N, Q, or V; X 2 is A, E, W or Y; X 3 is D, G, I, N, T, V, W, or Y; X 4 It is W; X 5 is E or W; X 6 is D, E or H; X 7 It is T, V, W; X 8 is A, H, I, T or V; X 9 is A, F, N, S or R; X 10 Yes R; X 11 is F, I, H or W; X 12 is L, T or V; X 13 is A, D, E, Q, R, S or Y; X 14 is A, E, I, L or Q; X 15 It is D, E, H, R, S or Y.
[0262] 8. An affinity reagent comprising a ligand that binds to a monoclonal antibody, antibody fragment, and antibody conjugate comprising a CH1 domain, the affinity reagent comprising a ligand that comprises at least one sequence of SEQ ID NOs: 6-152 and 154-204, or an amino acid sequence that differs by no more than 3, no more than 2, or no more than 1 substitution, addition, or deletion.
[0263] 9. The affinity reagent according to any one of claims 1-8, comprising a multimeric polypeptide comprising at least two subunits, each subunit being a polypeptide according to any one of embodiments 1-2.
[0264] 10. The affinity reagent of embodiment 9, wherein the subunits are not all identical.
[0265] 11. The affinity reagent of any one of embodiments 1-10, wherein the ligand is attached to a solid surface.
[0266] 12. The affinity reagent of embodiment 11, wherein the solid surface is a resin or a bead.
[0267] 13. The affinity reagent of embodiment 11, wherein the solid surface is a membrane.
[0268] 14. The affinity reagent of embodiment 11, wherein the solid surface is a monolith.
[0269] 15. The affinity reagent of any one of embodiments 11-14, wherein the ligand is conjugated to the solid surface via a linker.
[0270] 16. The affinity reagent of any one of embodiments 1-15, which is used for purifying monoclonal antibodies, antibody fragments and antibody conjugates containing a CH1 domain.
[0271] 17. A method for preparing an affinity reagent, comprising conjugating the ligand of any one of embodiments 1-14 to a solid surface.
[0272] Example
[0273] The examples given herein represent certain embodiments of the present invention. However, it should be understood that these examples are for illustrative purposes only and are not intended to nor should be construed as fully limiting the conditions and scope of the present invention. Unless otherwise described in detail, these examples are carried out using standard techniques, which are conventional techniques well known to those skilled in the art.
[0274] Example 1. Method
[0275] The peptides were synthesized by standard Fmoc solid phase peptide synthesis techniques and purified by preparative reverse phase HPLC. The purity of the peptides was assessed by RP-UPLC with UV and quadrupole time-of-flight mass spectrometry detection.
[0276] Recombinant affinity ligands are expressed in E. coli or Pichia pastoris using standard techniques. Ligands can be purified using multiple column chromatography. For His-tagged ligands, immobilized metal affinity chromatography (IMAC) is used as the primary capture step. Biotinylated ligands are expressed by AviTag TM System (Avidity, Aurora, CO). Non-biotinylated ligands bearing the AviTag sequence were prepared by omitting exogenous biotin. The purity and identity of the recombinant protein ligands were assessed by a combination of SDS-PAGE, RP UPLC, quadrupole time-of-flight mass spectrometry, and size exclusion chromatography (SEC; Sephadex S75, Cytiva, Marlborough, MA). In many cases, the ligands were isolated without the N-terminal methionine residue, which was presumably cleaved during expression.
[0277] Example 2. Exemplary CH1 Domain Affinity Ligands
[0278] This example demonstrates the binding of biotinylated ligands to Fab fragments or IgG with CH1 domains using biolayer interferometry (ForteBio, Menlo park, CA). Biotinylated affinity ligands were immobilized on the sensor and incubated with solutions containing different concentrations of Fab fragments or IgG. In order to demonstrate that the binding site is neither present on the light chain nor on the paratope (antigen binding site), the binding of two Fabs with different light chains and paratopes was studied. Figure 2 and Figure 3 Sensorgrams showing binding of affinity ligands 89, 90, and 92 to (a) Herceptin Fab (from the monoclonal antibody trastuzumab) having a kappa light chain (κ) and binding specificity for Her2 / neu or (b) Tremfya Fab (from the monoclonal antibody guselkumab) having a lambda light chain (λ) and binding specificity for IL23, respectively.
[0279] Binding curves were fitted using the ForteBio software with a 1:1 binding model to determine binding affinities, and the resulting data are shown in Table 1. As expected, the affinity ligand reagents bound to the two Fabs with different light chains, and the binding affinities were generally less than 100 nM, and in many cases less than 10 nM. Similar experiments with dimeric human IgG-λ (Southern Biotech, Birmingham AL) had the highest affinity of all the reagents tested.
[0280] Table 1 Affinity of selected ligands for Fab and antibody (K D )
[0281]
[0282] Example 3. Alkaline stability of affinity ligands
[0283] This example demonstrates the sodium hydroxide stability of affinity ligands. The affinity ligands shown were incubated in 0.1 M NaOH for 24 hours and then neutralized. The binding of the ligands after NaOH treatment was measured as described in Example 2 and compared to the untreated ligands. The retained binding was calculated according to the following formula:
[0284] Retained binding % = (measurement response after NaOH treatment) ÷ (measurement response without treatment) × 100
[0285] The data in Table 2 demonstrate that many of the affinity ligands tested exhibit high stability under the conditions tested.
[0286] Table 2 Binding percentage retained under alkaline conditions (%)
[0287]
[0288]
[0289] Example 4. Construction of an exemplary affinity resin
[0290] This example illustrates the production and characterization of affinity reagents comprising ligands identified and described herein. Affinity resins were prepared by conjugation with Jetted A50 beads (Purolite, King of Prussia, PA) or ABT700 (Agarose Bead Technologies, Madrid, Spain) agarose beads.
[0291] Bromoacetyl-activated beads were activated with disuccinimidyl carbonate and coupled with excess ethylenediamine followed by washing with bromoacetate to functionalize free amines. Affinity ligands were conjugated to bromoacetyl-activated beads via their carboxyl-terminal cysteine at room temperature using EDC activation (EDC is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride). Epoxy-activated beads can be obtained from commercial suppliers or prepared using standard methods well known in the art. Ligands were coupled to epoxy-activated beads at 37–40°C. Target ligand densities varied between 5–40 g / L. After washing, beads were inactivated with excess thioglycerol. Actual ligand density was determined using subtraction RP-HPLC according to the following formula:
[0292] Actual ligand density = ([ligand] measured in feed - [ligand] measured in effluent).
[0293] Example 5. Alkaline stability of affinity resin
[0294] This example demonstrates the binding properties and sodium hydroxide stability of affinity chromatography resins prepared by affinity ligands described herein. In short, 10 μL of affinity resin was aliquoted into duplicate wells on a 96-well filter plate and incubated for 24 hours in a neutral pH buffer or 0.1M NaOH containing 1M NaCl. After incubation, the affinity resin was thoroughly washed with a neutral pH buffer and the binding was determined in a batch manner. As listed in Table 3, after balancing with PBS, in repeated cycles of binding, each binding cycle was challenged with an IgG at a concentration of 0.5-2mg / mL for 15 minutes. After each binding challenge, the porous filter plate was centrifuged to separate unbound IgG from the resin, and the amount of unbound IgG was quantified by measuring the absorbance of the effluent at 280nm.
[0295] Table 3 Test procedures for affinity resin binding properties and alkaline stability
[0296]
[0297] Adsorption isotherms were constructed by plotting the concentration of IgG remaining in solution after incubation with the resin versus the amount of IgG bound to the resin under various challenge conditions. Figure 4-6 The adsorption isotherms of affinity resins with ligands of SEQ ID NO. 129, 134 and 144 are shown respectively. The results show that after exposure to 0.1 M NaOH containing 1 M NaCl for 24 hours, the resin with SEQ ID. 129 retains more than 94% of the binding, the resin with SEQ ID. 134 retains more than 88% of the binding, and the resin with SEQ ID. 144 retains more than 95% of the binding relative to the initial Qmax.
[0298] Example 6. Monoclonal Antibody Purification
[0299] Clarified cell culture feed stream (CCCF) from a CHO cell line containing a monoclonal antibody (MAb1) at an effective titer of 2.5 g / L was used to load an affinity resin prepared from the ligand corresponding to SEQ ID No. 129. The resin was packed into a 0.3 x 10 cm (0.707 mL) column and operated as shown in Table 4.
[0300] Table 4 Affinity purification of MAb1
[0301]
[0302]
[0303] Abbreviations in Tables 4-6: CV, column volume; V, velocity; CIP, cleaning in place.
[0304] Fractions were analyzed on a 4-12% Bis-Tris SDS-PAGE gel under non-reducing conditions. The samples loaded in each lane were (1) SeeBlue Plus2 molecular weight marker, (2) crude feed stream (i.e., CCCF), (3) 10-fold diluted crude feed stream, (4) flow-through fraction (i.e., chase), (5) wash fraction, (6) elution fraction (6.4 ug), and (7) wash fraction (i.e., CIP).
[0305] Example 7. Purification of monoclonal antibodies on CIP resin
[0306] The packed column was used to purify a monoclonal antibody with a titer of 2.5 mg / mL in CHO CCCF. Resins were prepared from ligands corresponding to SEQ ID NOs. 129, 134 and 144 as described in Example 4, loaded into a 0.3 x 10 cm (0.7 mL) column and operated as shown in Table 5.
[0307] Table 5 Affinity purification of monoclonal antibodies
[0308]
[0309]
[0310] Between each purification cycle, the resin was exposed to the CIP reagent for a total of 60 min to simulate 4 CIP cycles.
[0311] The eluted fractions from each purification cycle were collected and analyzed using Cygnus TM CHO Host Cell Protein Third Generation Assay and ThermoFisher Quant-iT TM PicoGreenTM The purity of residual host cell proteins (HCP) and residual host cell DNA (HCDNA) were analyzed separately. Figure 8 Figure a shows the purity of the eluted fractions obtained from the affinity resin reagent in 60 simulated cycles, with HCP less than 700 ppm for all cycles and less than 300 ppm for most cycles. Figure 8 As shown in the figure below, HCDNA was reduced to below 5 ppm for all three resins in all cycles. The data confirm that the resins can be cleaned with NaOH and reused multiple times.
[0312] Example 8. Purification yields.
[0313] In this study, the purified monoclonal antibody at a concentration of 2.36 mg / mL was loaded onto a 0.3 x 10 cm (0.7 mL) column packed with affinity resin having affinity ligand of SEQ ID. 144. Ten purification cycles were performed as described in Table 6. Between each cycle, the resin was exposed to CIP reagent 0.1 M NaOH, 1 M NaCl for 60 minutes, which was equivalent to 4 simulated CIP cycles. The yield was determined after each of the 10 cycles and was calculated at 1:1. Fig. 9 The simulated cycles are plotted in Figure 2. The data show that the resin can be cleaned with NaOH and reused multiple times while maintaining consistent productivity.
[0314] Table 6
[0315] Operating conditions for yield determination
[0316]
[0317]
[0318] Example 9. Effect of spiral resin
[0319] This example demonstrates that helices 2, 4, and 6 are not essential for binding. Modifications can be made to helices 2, 4, or 6 and as long as these modifications still allow the TPR to form a packed helical bundle with helices 1, 3, 5, and 7 forming the inner surface, the ligand will remain bound.
[0320] Example 10. Effect of spiral resin
[0321] The effect of sequence variation in helix 2 of the seven helices of these TPR domain-containing ligands was examined by determining the binding affinity of four biotinylated ligands that had identical sequences for helices 1, 3, 5, and 7, but different sequences for helix 2. Binding affinities were determined as described in Example 2, and the results are shown in Table 7. These results indicate that modifications made in helix 2 preserve ligand binding.
[0322] Table 7 Affinity of ligands with helix 2 for Fab and IgG (K D )
[0323]
[0324] Example 11. Binding of biotinylated ligands to monoclonal antibodies
[0325] This example uses biolayer interferometry to demonstrate that biotinylated ligands bind to IgG1 IgG2 and IgG4 Binding of monoclonal antibodies. Antibodies were obtained from McKesson Supply Manager (Irving, Tx). Biotinylated ligands were immobilized on the sensor and incubated with solutions containing different concentrations of monoclonal antibody protein. The binding affinities are shown in the table below.
[0326]
[0327]
[0328] Example 12. Binding of biotinylated ligands to mAB and Fab
[0329] This example demonstrates the binding of biotinylated ligands to intact mAb and Fab molecules. The biotinylated ligand corresponding to SEQ ID No: 181 was immobilized on the sensor and incubated with solutions containing different concentrations of trastuzumab or trastuzufab protein. Fig.10 As is evident from the dose response curves for binding shown, the ligand binds to both molecules with high affinity.
[0330] Example 13. Affinity resin with high binding capacity
[0331] This example demonstrates that affinity resins with high binding capacity can be obtained using the ligands of the present invention. Affinity resins were prepared using the ligand corresponding to SEQ ID No: 181 conjugated to epoxy-activated Jetted A50 agarose beads and loaded into a 3×50 mm column. and The binding capacity was obtained using a challenge concentration of 2 g / L at a residence time of 4 minutes. Fig.11 As shown, the 10% penetration values are listed in the table below.
[0332]
[0333] Example 14. NaOH stability of affinity resin column
[0334] This example demonstrates the NaOH stability of the affinity resin column of the previous example. After exposure of the resin to 1 M NaCl in 0.1 M NaOH, repeated DBC cycles were performed at the indicated time points and the DBC at 10% breakthrough was measured. Fig.12 The data shown in show that the resin showed no loss of binding capacity after exposure to 0.1 M NaOH containing 1 M NaCl for 24 hours.
[0335] Example 15. Purification of Antibodies
[0336] This example demonstrates the purification of antibodies from a crude feed stream and that the resin can be reused multiple times. The affinity resin of Example 13 was packed into a 0.3×10 cm column and challenged with a host cell clarified feed (HCCF) containing trastuzumab at an effective titer of 0.8 g / L. The column was operated as shown in the following table.
[0337]
[0338] During the "wash" step, the flow was stopped so that the total exposure time of the resin in 1 M NaCl in 0.1 M NaOH was 3.5 h per cycle, and the column was operated for 8 cycles. The yields obtained for each cycle were Fig.13 The residual HCP and DNA impurity levels obtained in each cycle are shown in Fig.14 and 15 Overall, the data demonstrate high purity and the ability to cycle the column without loss of performance.
[0339] With the benefit of the teachings given in the foregoing description and the associated drawings, those skilled in the art to which the present disclosure belongs will appreciate many modifications and other embodiments of the disclosure set forth herein. Therefore, it should be understood that the present disclosure is not limited to the specific embodiments disclosed, and modifications and other embodiments are intended to be included within the scope of the appended claims and the list of embodiments disclosed herein. Although specific terms are used herein, they are used only in a general and descriptive sense, not for the purpose of limitation.
[0340] Any method disclosed herein does not require execution in the order described. The methods disclosed herein include certain actions taken by a practitioner; however, they may also include any third party's explicit or implicit instructions for these operations.
[0341] Table 8 Sequence
[0342]
[0343]
[0344]
[0345]
[0346]
[0347]
[0348]
[0349]
[0350]
[0351]
[0352]
[0353]
[0354]
[0355]
[0356]
[0357]
[0358]
[0359]
[0360]
[0361]
[0362]
[0363]
[0364]
[0365]
[0366]
[0367]
[0368]
[0369]
[0370]
[0371]
[0372]
[0373]
[0374]
[0375]
Claims
1. An affinity ligand comprising, from N-terminus to C-terminus, an amino acid sequence represented by the following formula, [A]-AERWYDLGAYARGDX 17a DRAX 21a AND 23a YX 25a RX 27a SCARCE 30a DPND-AWAWWELGX 9b AYAARGDYDRAIYYQRALELDX 32b NN-AVAWRLGIAN 13c RGDYDRAIYYQRALELDDPNN-EVARX 5d ALEYARRX 13d -[B] in X 17a is F or Y; X 21a is I or T; X 23a is Y or F; X 25a is R or Q; X 27a is T or A; and X 30a is L or H; in X 9b is V or I; and X 32b is L, P or T; in X 13c is T or A; in X 5d is D or G, and X 13d is A or V; and in [A] is present or absent, and when present comprises M, MDE, MGGGGSAAAGDE, MGDE, MGHHHHHHDE, MGLAEAAAREAAARAADE, or MAWAEFRQRLAAIRTRLEALGGSEAELAAFEREIAAFESELQAYAGAGNPEVEALRREAAAIRDELQAYRHNDE; and [B] is present or absent, and when present comprises cysteine, RRC, RRCHHHHHH, or RRGQAGQGGGSGLNDIFEAQKIEWHECHHHHHH.
2. The affinity ligand according to claim 1, wherein X 17a It is F;X 21a is I; X 23a It is Y; X 25a Yes R; X 27a It is T; X 30a Yes L; X 9b It is V; X 32b It is P; X 13c It is T; X 5d is D; and X 13d It's V.
3. The affinity ligand according to claim 1, wherein X 17a It is Y; X 21a It is T; X 23a It is F;X 25a It is Q; X 27a It is A; X 30a Yes L; X 9b is I; X 32b It is P; X 13c It is A; X 5d is D; and X 13d It is A.
4. The affinity ligand according to claim 1, wherein X 17a It is Y; X 21a is I; X 23a It is Y; X 25a It is Q; X 27a It is A; X 30a Yes H; X 9b It is V; X 32b It is T; X 13c It is A; X 5d is G; and X 13d It is A.
5. The affinity ligand according to claim 1, wherein X 17a It is Y; X 21a is I; X 23a It is Y; X 25a It is Q; X 27a It is A; X 30a Yes L; X 9b It is V; X 32b Yes L; X 13c It is A; X 5d is D; and X 13d It is A.
6. The affinity ligand according to any one of claims 1 to 5, wherein [A] is MGHHHHHHDE and [B] is RRC.
7. The affinity ligand according to any one of claims 1 to 5, wherein [A] is MGLEAAAAAREAAARAADE and [B] is RRCHHHHHH.
8. The affinity ligand according to claim 2, wherein the ligand comprises any one of SEQ ID NO: 89, 128, 130, 131 or 132 (ligand 129 group).
9. The affinity ligand according to claim 3, wherein the ligand comprises any one of SEQ ID NO: 90, 133, 135, 136 or 137 (ligand 134 group).
10. The affinity ligand according to claim 4, wherein the ligand comprises any one of SEQ ID NO: 139, 140, 141 or 143 (ligand 141 group).
11. The affinity ligand of claim 5, wherein the ligand comprises any one of SEQ ID NO: 86, 91, 138, 142, 144, 145, 146, 147 or 148 (ligand 144 group).
12. The affinity ligand of claim 1, wherein the ligand comprises any one of SEQ ID NOS: 129, 134, 141 or 144.
13. The affinity ligand according to any one of claims 1 to 12, further comprising a C-terminal cysteine or lysine.
14. A multimer comprising a plurality of affinity ligands according to any one of claims 1 to 13.
15. The multimer according to claim 14, which is a dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer or nonamer.
16. The affinity ligand or multimer according to any one of claims 1 to 15, wherein the ligand or multimer further comprises at least one heterologous agent operably linked to the affinity ligand to form a conjugate or fusion protein.
17. The affinity ligand or polymer of claim 16, wherein the heterologous agent is selected from the group consisting of: one or more small molecule diagnostic or therapeutic agents; peptide tags, DNA, RNA or hybrid DNA-RNA molecules; traceable labels; radioactive materials; antibodies; single chain variable domains; and immunoglobulin fragments.
18. A separation matrix comprising at least one affinity ligand according to any one of claims 1 to 13 or at least one multimer according to claim 14 or 15.
19. The separation matrix of claim 18, wherein the affinity ligand or polymer is coupled to a solid support.
20. The separation matrix of claim 19, wherein the affinity ligand or polymer is coupled to the solid support via a thiol bond.
21. The separation matrix according to any one of claims 18 to 20, wherein the solid support is a chromatography resin or matrix.
22. The separation matrix of claim 21, wherein the solid support is a cross-linked agarose matrix.
23. A method for isolating an antibody comprising a CH1 domain or a fragment thereof comprising a CH1 domain, comprising contacting the antibody or the fragment with the separation matrix according to any one of claims 18 to 22, and recovering the antibody or the fragment thereof.
24. The method according to claim 23, comprising (a) contacting the separation matrix of any one of claims 18 to 22 with a composition comprising the antibody or the fragment, (b) washing the separation matrix with a wash buffer, (c) eluting the antibody or the fragment from the separation matrix with an elution buffer, and (d) recovering the antibody or the fragment.
25. The method of claim 23 or 24, further comprising (e) treating the separation matrix with an alkaline cleaning solution for a period of time sufficient to clean the matrix of residual material and regenerate at least 80% of the antibody or antibody fragment binding capacity of the separation matrix.
26. The method of claim 25, wherein the alkaline cleaning solution comprises about 0.1 M NaOH to about 0.5 M NaOH.
27. The method of claim 25 or 26, wherein the separation matrix retains at least 80% of its antibody or antibody fragment binding capacity when steps (a)-(e) are repeated at least 10 times.
28. The method of any one of claims 25 to 26, wherein steps (a) to (e) are repeated at least 10 times with a single batch of separation matrix.
29. A nucleic acid or vector encoding the affinity ligand of any one of claims 1 to 13 or the multimer of claim 14 or 15.
30. An expression vector comprising the nucleic acid or vector of claim 29, wherein the coding region of the affinity ligand is operably linked to one or more expression control elements.
31. A host cell comprising the nucleic acid or vector of claim 29 or 30.
32. The host cell of claim 31, wherein the host cell is Escherichia coli or Pichia pastoris.
33. A method for preparing a separation matrix, the method comprising conjugating a ligand according to any one of claims 1 to 13 or a multimer according to claim 14 or 15 to a solid surface.
34. An affinity reagent, comprising a ligand, wherein the ligand comprises a TPR ligand comprising 7 helices, wherein the first helix comprises the sequence SEQ ID No: 1 X 1 RxF 2 X 3 , where X 1 is A, D, E, G, N, Q, S, or V; X 2 is A, E, W or Y; X 3 is D, G, H, I, N, T, V, W or Y; The third helix comprises the sequence SEQ ID NO:2 X 4 AWX 5 X 6 LGX 7 , where X 4 It is W; X 5 is E or W; X 6 is D, E or H; X 7 It is T, V, W; The fifth helix comprises the sequence SEQ ID NO:3 X 8 AWX 9 X 10 LGX 11 , where X 8 is A, H, I, T or V; X 9 is A, F, N, S or R; X 10 Yes R; X 11 is F, I, H or W; The seventh helix comprises the sequence SEQ ID NO:4 X 12 ARX 13 X 14 LEX 15 , where X 12 is A, L, T or V; X 13 is A, D, E, H, Q, R, S, or Y; X 14 is A, E, I, L, N or Q; X 15 Is A, D, E, H, N, R, S, V, or Y.
35. The affinity reagent of claim 34, which binds to a monoclonal antibody, an antibody fragment, and an antibody conjugate containing a CH1 domain.
36. An affinity reagent comprising a ligand that binds to a monoclonal antibody, antibody fragment, and antibody conjugate comprising a CH1 domain, the affinity reagent comprising a ligand that comprises at least one sequence of SEQ ID NOs: 6-152 and 154204, or an amino acid sequence that differs by no more than 3, no more than 2, or no more than 1 substitution, addition, or deletion.
37. The affinity reagent according to any one of claims 34-35, which comprises a multimeric polypeptide comprising at least two subunits, each of which is a polypeptide according to any one of claims 34-35.
38. An affinity reagent according to claim 37, wherein the subunits are not all identical.
39. The affinity reagent of any one of claims 34-38, wherein the ligand is attached to a solid surface.
40. The affinity reagent of claim 39, wherein the solid surface is a resin or a bead.
41. The affinity reagent of claim 39, wherein the solid surface is a membrane.
42. The affinity reagent of claim 39, wherein the solid surface is a monolith.
43. The affinity reagent of any one of claims 39-42, wherein the ligand is conjugated to the solid surface via a linker.
44. The affinity reagent according to any one of claims 34 to 43, which is used for purifying monoclonal antibodies, antibody fragments and antibody conjugates containing a CH1 domain.
45. A method of preparing an affinity reagent comprising conjugating a ligand according to any one of claims 34-38 to a solid surface.
